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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic obstructive pulmonary disease (COPD) is characterized by persistent 
airflow limitation and loss of alveolar structures, causing respiratory symptoms (1). 
Specific symptoms of this progressive disease can include dyspnea, chronic cough, 
increased sputum production and increased susceptibility to respiratory infections. 
COPD is the third cause of death worldwide and claimed 3 million lives in 2016 (2). A 
prevalence of 600,000 patients in the Netherlands is estimated (3). Tobacco smoking 
is the most important risk factor for developing COPD, but occupational exposure, 
air pollution, biomass smoke and genetic predisposition may also contribute (4). 
COPD can be categorized in a spectrum of phenotypes, including airway disease 
(bronchitis) and lung parenchymal destruction (emphysema) (1). In patients with 
the emphysema phenotype, lung parenchyma destruction leads to reduced 
gas exchange, loss of alveolar attachments to the small airways and diminished 
protective elastic recoil forces on the airways (figure 1) (1). These structural 
changes cause increased airway collapsibility, leading to both airflow limitation 
and airtrapping, thereby causing increased static and dynamic hyperinflation (1). 
Figure 1: Computed tomography scan of the lung showing severe bilateral emphysema (A). The 
circle indicates the area that was endoscopically visualized. Transthoracic endoscopic view of the 
left upper-lobe lung emphysematous parenchyma (B and C). Reprinted with permission of the 
American Thoracic Society. Copyright © 2019 American Thoracic Society. Dirk-Jan Slebos, Karin 
Klooster and Michiel Erasmus. 2012. Emphysema!. AJRCCM. Vol 186, Iss. 2, p 197.
TREATMENT OF COPD
No definitive cure for COPD is available, and all current treatment options for COPD 
are aimed at relieving symptoms and slowing down disease progression. Treatment 
options include: smoking cessation, bronchodilators, anti-inflammatory agents, 
oxygen therapy, pulmonary rehabilitation, vaccination, nutritional support, non-
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invasive ventilation and surgical interventions such as lung transplantation, lung 
volume reduction and more recently bronchoscopic lung volume reduction (BLVR).
The studies in this thesis specifically focus on lung volume reduction techniques. 
The physiological rationale behind lung volume reduction treatments is that the 
reduction of static and dynamic hyperinflation reduces dead space, decreases 
alveolar compression, increases elastic recoil, improves chest wall motion and 
restores the diaphragmatic function (5).
Lung volume reduction surgery
Lung volume reduction surgery is a treatment for patients with the severe 
emphysema phenotype of COPD, aimed at reducing lung hyperinflation by resecting 
the most diseased portions of the lung (6). Lung volume reduction surgery increases 
the elastic recoil of the lung, leading to improved expiratory flow rates and reduced 
COPD exacerbations (7,8). The National Emphysema Treatment Trial (NETT), a large 
multicentre clinical trial in the United States, documented improved exercise 
capacity, quality of life and dyspnea after lung volume reduction surgery compared 
to regular medical therapy, but these benefits came at the price of increased short 
term mortality and morbidity (6). However, the improvement of surgical techniques, 
strict patient selection and specialized centers may result in lower morbidity and 
mortality after lung volume reduction surgery (9).
Development of bronchoscopic lung volume reduction techniques
The mixed outcomes of the NETT stimulated the development of several 
bronchoscopic lung volume reduction treatment techniques. The goal of these 
techniques is to endoscopically induce collapse of areas of the hyperinflated 
emphysematous lung, to achieve a beneficial effect similar to lung volume reduction 
surgery, but without the morbidity of this surgery (6). Different minor invasive 
bronchoscopic lung volume reduction approaches have been developed and 
include endobronchial one-way valves, endobronchial coils, lung sealants, steam 
vapour ablation and airway bypass techniques (10–18). Endobronchial valves and 
endobronchial coils, the bronchoscopic lung volume reduction approaches that 
have been studied most extensively, have been demonstrated to both be safe and 
effective in several clinical trials (10–15). Bronchoscopic lung volume reduction 
using lung sealants and steam vapour ablation is still in development (16,19). The 





PATIENT SELECTION FOR BRONCHOSCOPIC LUNG VOLUME 
REDUCTION
In order to achieve safe and clinically meaningful results after bronchoscopic lung 
volume reduction treatment, it is essential to carefully select patients for these 
treatments. All patients with emphysema who are considered for bronchoscopic lung 
volume reduction treatment should be on optimal medical therapy, have stopped 
smoking for at least 6 months and should have completed clinical pulmonary 
rehabilitation and/or are participating in weekly maintenance physical therapy 
(20). Other important selection criteria are: increased lung hyperinflation (residual 
volume (RV) >175% of predicted, RV/Total lung capacity (TLC) ratio >0.58), presence 
of significant emphysema, and for endobronchial valve treatment, the presence of 
intact interlobar fissures and thus absence of collateral ventilation.
Previous studies have investigated the reasons for bronchoscopic lung volume 
reduction treatment ineligibility in clinical practice (21). However, the population 
referred for BLVR treatment is not yet well characterized in the available literature. 
Studies investigating which proportion of patients that are referred for BLVR 
treatment, are actually selected for these treatments are needed to improve 
future patient selection and referral. In addition, new insights obtained during the 
development of BLVR techniques, have caused the inclusion and exclusion criteria 
for these treatments to change over time. For example, the presence of alpha-1 
antitrypsin deficiency, a genetic predisposition for developing emphysema was 
considered a contra-indication for trials investigating endobronchial valves, but 
these patients are now considered eligible for treatment (10,22).
Lung hyperinflation
All bronchoscopic lung volume reduction techniques are aimed at the reduction of 
hyperinflation of the lung. The evaluation of lung function is therefore an essential 
component of patient selection for bronchoscopic lung volume reduction (20). The 
assessment of hyperinflation can be performed using different approaches, but 
the most frequently applied methods are body plethysmography and helium gas 
dilution (23). Body plethysmography is the preferred method to assess RV in patients 
with severe emphysema, as gas dilution techniques tend to underestimate lung 
volumes because of airway obstruction and emphysematous destructed areas in the 
lung with very poor ventilation, preventing the gas to reach all regions of the lung 
(24). In order to qualify for bronchoscopic lung volume reduction treatment, body 
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plethysmography testing should demonstrate significant hyperinflation of the lung, 
defined as RV >175% of predicted and RV/TLC ratio of >0.58 (20).
Interlobar collateral ventilation assessment for endobronchial valve treatment
The purpose of endobronchial valve treatment is to induce lobar atelectasis by 
occluding all segmental bronchi of a destructed and hyperinflated lobe with one-
way valves (20). Endobronchial valve treatment can only be successful in the absence 
of interlobar collateral ventilation, as the presence of interlobar collateral ventilation 
prevents the desired lobar atelectasis (10). Collateral ventilation is defined as “the 
ventilation of alveolar structures through passages or channels that bypass the 
normal airways” (25).
Collateral ventilation can be assessed using direct and indirect techniques, the 
direct technique involves the Chartis measurement (Pulmonx Inc., Redwood City, 
CA, USA), during which a catheter with an inflatable balloon at the tip is used during 
bronchoscopy to assess the presence of collateral ventilation (26). Indirect techniques 
to assess collateral ventilation include the use of quantitative computed tomography 
(CT) analysis to assess interlobar fissure integrity, a predictor for interlobar collateral 
ventilation (26). The Chartis measurement is started with the inflation of the balloon 
at the tip of the catheter, allowing for selective occlusion of the lobe to be measured 
(27). The system is then able to measure expiratory airflow from the occluded lobe, 
with decreasing airflow over time indicating the absence of collateral ventilation, 
whilst persistence of airflow suggests the presence of collateral ventilation (27).
Measurement of collateral ventilation using Chartis was initially validated in 
patients using procedural sedation (28,29). However, given the challenging nature 
of performing the Chartis measurement under procedural sedation (increased 
coughing, mucus secretion and difficulties maintaining the right level of sedation), 
in clinical practice the measurement is also performed under general anesthesia. 
The effects of the two anesthesia techniques, on the outcomes and feasibility of 
measurements, have not yet been compared in the literature.
Performing a Chartis measurement can be complicated by the no flow phenomenon, 
during which a sudden cessation of flow is observed, caused by dynamic expiratory 
airway collapse, preventing reliable assessment (30).When this occurs in the right 
lower lobe, measurement of the right major fissure in the right upper lobe is not 




selective temporary occlusion of the right middle lobe using a blocking device may 
help in obtaining a reliable Chartis outcome.
Target lobe selection for endobronchial valve treatment
Selection of the most suitable lobe (“the target lobe”) for endobronchial valve 
treatment is based on the degree of emphysema destruction, lobar volume of the 
target and ipsilateral lobe, heterogeneity between both lobes, absence of collateral 
ventilation, absence of pleural adhesions and low lobar perfusion assessed using 
perfusion scintigraphy (20,27,31). Target lobe selection for endobronchial valve 
treatment can be a challenging task, especially in patients with more than one 
suitable target lobe or a very homogeneous emphysema distribution. Considering 
that current target lobe selection is predominantly based on imaging methods 
that provide indirect information about lung function, there is a need for the 
development of more direct measurement methods that can aid in target lobe 
selection (32).
ASSESSMENT OF TREATMENT EFFECT
The assessment of treatment effect after bronchoscopic lung volume reduction can 
be performed using different approaches: a first approach is to evaluate treatment 
effect based on change in clinical parameters. These clinical parameters may include 
pulmonary function tests outcomes, for example forced expiratory volume in 1 
second or residual volume, exercise capacity measured using the 6-minute walking 
test or radiological outcomes such as quantitative assessment of target lobe volume 
reduction on a chest high resolution CT (HRCT) scan (33–35).
While the evaluation of treatment based on clinical parameters might be the more 
objective approach, the integration of patient reported outcomes is important as 
it captures the patients perspective (36). In addition, changes in clinical parameters 
do not necessarily reflect improvement in symptoms experienced by the patient 
(37). Finally, some symptoms, such as dyspnea, cannot be assessed objectively (37).
Therefore, a second approach is to evaluate treatment effect based on patient 
reported outcomes, for example using quality of life questionnaires. One of the most 
widely used methods to assess quality of life in patients with COPD, is the St. George’s 
Respiratory Questionnaire, which is a validated, self-completed questionnaire (38).
15
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The minimal important difference
After bronchoscopic lung volume reduction treatment, changes in clinical parameters 
and patient reported quality of life are evaluated by analysing differences in these 
parameters before and after treatment using statistical tests. However, it is important 
to assess whether statistically significant changes in outcome parameters are actually 
meaningful for the patient, since this is not necessarily the case. One method to 
assess meaningful improvement after treatment is the minimal important difference, 
which is a threshold value for the clinically relevant change on the individual level; 
patients who achieve this threshold are considered responders to the treatment (37). 
The minimal important difference for the St. George’s Respiratory Questionnaire 
has been established previously (39). However, the established minimal important 
difference might not be applicable for patients with severe emphysema, especially 
those who undergo bronchoscopic lung volume reduction treatments, as this group 
was not included in previous minimal important difference calculations.
Radiological evaluation
Radiological evaluation using HRCT scans of the chest is a key element in both the 
selection of potential bronchoscopic lung volume reduction candidates as well as 
assessment of treatment effect after bronchoscopic lung volume reduction (20). 
Quantitative CT analysis may aid in quantifying the severity of emphysematous 
destruction, distribution of emphysema, lobar volumes and fissure integrity (40). 
After bronchoscopic lung volume reduction treatment, HRCT scans are performed 
to assess target lobe volume reduction and to identify potential complications. 
The currently used, but expert opinion-based cut-off value for target lobe volume 
reduction is 350ml, however a formal minimal important difference for target lobe 
volume reduction has not yet been established.
AIMS AND OUTLINE OF THE THESIS
The aim of this thesis is to advance bronchoscopic lung volume reduction treatment 
in patients with severe emphysema, in particular by improving patient selection for 
bronchoscopic lung volume reduction treatment and by improving the identification 
of patients with a meaningful clinical improvement after bronchoscopic lung volume 
reduction treatment.
In chapter 2 we review the available literature on the efficacy and safety of lung 




In chapter 3 we investigate a large cohort of patients that was referred to our 
hospital for assessment of bronchoscopic lung volume reduction eligibility. Our 
goals are to investigate which proportion of patients that were referred for BLVR 
were actually selected for bronchoscopic lung volume reduction treatment and to 
investigate the differences between patients that were selected and not selected 
for BLVR.
In chapter 4 the results of a study on the differences in body plethysmography 
outcomes between patients referred for bronchoscopic lung volume reduction 
to our hospital and their referring hospitals will be presented, highlighting the 
importance of dedicated pulmonary function testing.
Chapter 5 describes a study in which we investigate whether a new endoscopic 
oxygen uptake measurement, designed for identification of the least functional 
lobe of the lung, can be used as an additional tool supporting target lobe selection 
for endobronchial valve treatment.
In chapter 6 and chapter 7 we investigate in a both retrospective and prospective 
fashion, the effect of anesthesia technique (procedural sedation versus general 
anesthesia) on the outcomes and feasibility of endoscopic measurement of interlobar 
collateral ventilation (Chartis measurement).
In chapter 8 we present a case series of patients, in which we investigate whether 
temporary right middle lobe occlusion using a blocking device is helpful to perform 
a reliable right upper lobe Chartis measurement of the right major fissure, in case of 
the no flow phenomenon in the right lower lobe.
Chapters 9 and 10 of this thesis are aimed at improving the identification of clinical 
responders after bronchoscopic lung volume reduction treatment. In order to 
achieve this goal we re-evaluate the current minimal important differences for the 
St. George’s Respiratory Questionnaire, a frequently used quality of life measurement 
outcome in patients with COPD (chapter 9), and in addition establish a new minimal 
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Lung volume reduction with endobronchial coils 
for patients with emphysema
Jorrit B.A. Welling
Dirk-Jan Slebos




The lung volume reduction coil treatment is a minimally invasive bronchoscopic 
treatment option for emphysema patients who suffer from severe hyperinflation. 
The treatment is aimed at a large group of patients where lung volume reduction 
surgery and bronchoscopic lung volume reduction using endobronchial valves are 
no option, or alternatively, can be offered as a bridge to lung transplantation.
The nitinol coil exhibits a shape memory effect and is biologically inert. The lung 
volume reduction coil procedure is performed in two separate treatment sessions, 
targeting one lobe per session, with the contralateral lobe being treated 4 to 8 
weeks after the first session. In one treatment session, around 10 to 14 coils, thereby 
treating an entire lobe, are being placed. Selecting optimally treated, symptomatic 
chronic obstructive pulmonary disease (COPD) patients with emphysema and severe 
hyperinflation, while avoiding significant airway disease such as asthma, chronic 
bronchitis and bronchiectasis, is key to achieve treatment success. Three randomized 
clinical trials investigating lung volume reduction coil treatment have been 
published until now, reporting the results of 452 treated patients up to 12 months 
after coil treatment. Lung volume reduction coil treatment results in significant 
improvement of pulmonary function outcomes and quality of life in patients with 
severe hyperinflation. The most common complications of lung volume reduction 
coil treatment are: COPD exacerbations, pneumonia, Coil Associated Opacity and 
an increased risk of pneumothorax. The purpose of this article is to describe the coil 
technique and review the available literature regarding effect, safety and future 
perspectives of lung volume reduction with coils for emphysema patients.
BACKGROUND
Emphysema is characterized by lung parenchymal destruction caused by tobacco 
smoking, inhalation of other toxic agents, together with predisposed genetic host 
factors such as α1-antitrypsin deficiency (1). Lung parenchymal tissue destruction in 
severe emphysema is associated with increased lung elasticity, loss of elastic recoil, 
expiratory airway collapse, leading to static as well as dynamic hyperinflation and 
causing a significant reduction of lung function, exercise capacity and quality of life.
For patients with severe emphysema, the current available treatment options 
are: smoking cessation, bronchodilators, anti-inflammatory agents, vaccinations, 
proper nutrition, pulmonary rehabilitation, the use of oxygen, chronic non-invasive 
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ventilatory support and surgical interventions like lung volume reduction surgery 
and lung transplantation. Despite all these available treatment options, the majority 
of patients still remains highly symptomatic or do not qualify for surgical techniques.
Several minimal invasive bronchoscopic treatment options for severe emphysema 
have emerged, such as endobronchial valves (2), lung volume reduction coils (3) 
and more experimental techniques such as bronchoscopic thermal vapor ablation 
(4) and biological lung volume reduction (Aeriseal lung sealant) treatment (5), all 
aiming at reducing hyperinflation (6). Also very new airway directed treatments such 
as targeted lung denervation (7) and metered liquid nitrogen cryospray (8) are in 
development. Hyperinflation is known to play a key role in the feelings of dyspnea 
and reduced exercise capacity in emphysema (9,10). Targeting this hyperinflation 
component might significantly relief dyspnea and increase quality of life and 
exercise performance (2,11).
Depending on appropriate patient selection and correct placement, endobronchial 
valves reduce hyperinflation which manifests in clinical improvement (12). 
Responders to valve therapy are only patients with absence of interlobar collateral 
flow (assessed by quantitative CT fissure analysis, and/or the Chartis® catheter 
system) between the target lobe and adjacent lobe (2,13,14).
For patients with presence of interlobar collateral ventilation, of which prevalence 
is estimated to be around 60% in severe emphysema (15), coils might be a potential 
treatment option (16).
LUNG VOLUME REDUCTION WITH COILS
The coil
The RePneu® coil treatment (RePneu® coil system, PneumRx Inc./BTG, Santa Clara, 
CA, USA) is a bronchoscopic therapy for the treatment of patients with severe 
emphysema. The coil consists of a nickel-titanium alloy (nitinol) which exhibits 
a shape memory effect and is biologically inert (figure 1). The first application 
in humans was performed in 2008 after extensive testing of the treatment in 
animal models (17). The coil is produced in 3 different sizes (100/125/150mm) to 




Figure 1: RePneu Coil (125mm); used with permission of PneumRx/BTG.
Treatment procedure
The procedure is preferably performed with the patient undergoing general 
anesthesia, using a 9mm flexible endotracheal tube with pressure controlled 
ventilation at a low ventilation frequency (~10/min) with an inspiratory/expiratory 
ratio of about 1:4 to allow sufficient expiration in these severely air-trapped patients. 
Normally, patients remain hospitalized one night for regular observation after 
treatment. All our patients receive both corticosteroids (prednisolone 30mg per 
day), from the pre-treatment day up to 5 days after treatment, as well as antibiotic 
prophylaxis (azithromycin 250mg per day) starting on the treatment day up to 30 
days post treatment (expert opinion).
The coil placement procedure is, for safety reasons, performed in two separate 
treatment sessions, targeting one lobe per session, the contralateral lobe being 
treated 4 to 8 weeks after the first session. Bilateral treatment is necessary to achieve 
optimal treatment benefit (3). The most diseased lobes should be treated, identified 
using quantitative CT analysis and when needed perfusion scanning as guidance. 
Coil placement is performed using a bronchoscope with a therapeutic size working 
channel (2.8mm internal diameter or larger). It is recommended to take a routine 
microbacterial culture sample during the first inspection of the bronchial tree, this 
to be optimally informed about airway colonization, with respect to potential future 
infectious events.
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The coils are delivered, bronchoscopically, into the segmental and subsegmental 
airways using a special catheter delivery system. Placement is performed under 
fluoroscopy to visualize positioning and coil sizing (figure 2). The procedure starts 
with a guidewire, bearing fluoroscopic markers, that is used to measure airway length 
and to position the coil at a fair distance from the pleura (to avoid pneumothorax 
and pleural pain). When the guidewire is in the correct position, a delivery catheter 
can be advanced over the guidewire. The coils are situated in this delivery catheter 
in a straight configuration. When the target treatment area is reached, the 
delivery catheter is pulled back and the coil reverts to its non-straightened coil 
shape, resulting in a compression of the local lung parenchyma. The coil can then 
subsequently be released.
 
Figure 2: Coil treatment radiological imaging. Panel A: Fluoroscopic image during coil treatment 
of the right upper lobe in a severe emphysema patient. Panel B: Chest X-ray after treatment with 
coils.
 
In one treatment session, around 10 to 12 coils for upper lobes and 10 to 14 coils for 
lower lobes, are being placed in the desired lobe. During the procedure the coils can 
be removed and repositioned. The coil treatment is regarded permanent. However, 
when for example persistent thoracic pain requires removal of one coil, this has 
been shown feasible up to 10 months after implantation in specialist centers (18).
Mechanism of action
The hypothesized mechanism of action of the coil treatment is that the compression 
of the lung parenchyma by the coils results in less hyperinflation and simultaneously 




effect (19). Secondly, the coils reduce airflow towards the targeted segments of the 
lung and this consequently results in a redistribution of airflow towards healthier 
parts of the lung (20). Furthermore, a decrease in airway resistance occurs in the 
treated lobes (19,21). Finally, the volume reduction of the emphysematous treated 
areas could improve lung compliance and put the diaphragm in a better condition 
of function with, as a consequence, an increase in driving pressure of the expiratory 
flows (19,22,23).
Feasibility & efficacy
An overview of all published original coil studies is presented in table 1.
The first pilot study on coil treatment started in 2008 in Heidelberg (Germany). Eleven 
patients were treated with up to 6 coils per lobe, demonstrating both feasibility and 
safety, but no statement on efficacy could be made (17).
The second pilot study started in 2009 in Groningen (The Netherlands). Sixteen 
patients were treated, demonstrating safety, feasibility and efficacy of the procedure 
by using the second generation of the coil and increasing the number of coils per 
treated lobe to 10-12. At six months follow-up after the final treatment, there were 
significant improvements of -14.9 points (P<0.001) in St. George’s Respiratory 
Questionnaire (SGRQ), -11.4% (P<0.001) in residual volume (RV), +84.4 meter (P<0.001) 
in 6 minute walking distance (6MWD) and +14.9% (P=0.004) in forced expiratory 
volume in 1 second (FEV1), compared to baseline (24).
The third study and first randomized controlled trial investigating coils was the 
RESET trial (Endobronchial coils for the treatment of severe emphysema with 
hyperinflation). Forty-six patients with both homogeneous and heterogeneous 
emphysema were allocated in a one-to-one ratio to either coil treatment (treatment 
group) or best medical care (control group). Patients were treated in two sessions, 
with the contralateral lobe being treated 1 month after the initial treatment. Outcome 
measures were performed 90 days after the final treatment or the equivalent visit for 
the usual care group. Differences between treatment and best medical care group 
scores in change from baseline were -8.4 points (P=0.04) in SGRQ, -0.31L (P=0.03) in 
RV, +63.6 meter (P<0.001) in 6MWD and +10.6% (P=0.03) in FEV1 at 90 days follow-up 
after the final treatment (25).
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The fourth study, an open label feasibility study, investigating coils in strict 
homogeneous emphysema, confirmed the efficacy of treatment for this phenotype. 
At 6 months follow-up after treatment, there were significant improvements of -15 
points (P=0.028) in SGRQ, -0.6L (P=0.007) in RV, +61 meter (P=0.005) in 6MWD and 
+18.9% (not significant, P=0.102) in FEV1, compared to baseline (21).
The fifth study, a European open-label feasibility study including 60 patients, 
confirmed the previously published single center results in a multicenter design 
with a good safety profile and sustained results up to 12 months follow-up. At 12 
months follow-up after treatment, there were significant improvements of -11.1 
points (P<0.001) in SGRQ, -0.71L (P<0.001) in RV, +51.4 meter (P=0.003) in 6MWD 
and 0.11L (P=0.037) increase in FEV1, compared to baseline (26).
The sixth study and second randomized controlled trial was the REVOLENS trial 
(Lung Volume Reduction Coil Treatment versus Usual Care in Patients With Severe 
Emphysema). One hundred patients were allocated in a one-to-one ratio to either 
coil treatment or usual care. Contralateral treatment took place 1 to 3 months after 
the first. Approximately 10 coils per targeted lobe were delivered. All patients were 
assessed at baseline and at 1,3,6 and 12 months after baseline. Differences between 
treatment and usual care group scores in change from baseline were -13.4 points 
(P<0.001) in SGRQ, -0.37L (P=0.01) in RV, +21 meter (not significant, P=0.06) in 6MWD 
and +11% (P=0.01) in FEV1 at 6 months post treatment (27).
The seventh study and third randomized controlled trial was the RENEW trial (Effect 
of Endobronchial Coils versus Usual Care on Exercise Tolerance in Patients With 
Severe Emphysema), including 315 patients. Differences between treatment and 
usual care group scores in change from baseline were -8.9 points (P<0.001) in SGRQ, 
-0.31L (P=0.01) in RV, +14.6 meter (P=0.02) in 6MWD and +7% (P<0.01) adjusted 
median increase in FEV1 at 12 months post treatment. The greatest improvements 
occurred in the residual volume ≥225% predicted subgroups, in both heterogeneous 
and homogeneous emphysema phenotypes, highlighting the importance of the 
presence of hyperinflation (11).





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The most common complications of coil treatment are: COPD exacerbations, 
pneumonia, Coil Associated Opacity and an increased risk of pneumothorax 
(11,25,27).
In a 2015 meta-analysis, including 140 patients, no serious adverse events occurred 
periprocedural in any of the 259 coil procedures and no deaths or respiratory 
failures were reported. A total of 37 severe COPD exacerbations and 27 pneumonias 
requiring hospitalization were recorded among all patients up to 1 year of follow-up. 
Pneumothorax occurrence for which chest tube insertion was required was 6.4% per 
patient treated. Severe COPD exacerbation incidence was 3.1% in the first month 
after treatment, 2.9% per month from 1 month to 6 months after treatment and 2.3% 
per month from 6 months up to 1 year follow-up. Pneumonia incidence was 3.5% per 
month during the first month after treatment, 1% from 1 month to 6 months after 
treatment and 2.1% per month from 6 months up to 1 year follow-up (3).
Coil Associated Opacity, a phenomenon first described by the “RENEW” study 
investigators, is a noninfectious, localized tissue response that occurs post-
coil implantation in approximately 5-10% of cases. Coil Associated Opacity is 
hypothesized to be induced by stress forces from the coils on lung parenchyma. 
Patients with Coil Associated Opacity can demonstrate symptoms comparable to 
infectious pneumonia and this makes it difficult to distinguish between them. A 
chest radiograph of a patient with Coil Associated Opacity is provided in figure 3. 
Patients with Coil Associated Opacity exhibited superior 12-month effectiveness 
outcomes compared to patients without Coil Associated Opacity or pneumonia (11).
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Figure 3: Coil Associated Opacity. Panel A: Post-treatment chest X-ray displaying a mild 
consolidation around the coil position (“Coil Associated Opacity”) in the right lung. Panel B: Chest 
X-ray 12 months post-treatment in the same patient showing significant volume reduction in 
both upper lobes due to a post inflammatory fibrotic crowding reaction of the coils resulting in a 
beneficiary outcome.
Patient selection criteria
Coils are a potential treatment option for patients who do not qualify for 
endobronchial valve treatment (due to for example positive interlobar collateral 
ventilation status (16)) or lung volume reduction surgery, and can also be offered 
as a bridge to lung transplantation. Selecting optimally treated, symptomatic COPD 
patients with emphysema and severe hyperinflation (absolute minimal criteria for 
hyperinflation: RV>200% predicted and RV/TLC ratio >58%, measured using body 
plethysmography), while avoiding significant airway disease such as asthma, 
chronic bronchitis and bronchiectasis, is key to achieve treatment success (12,28,29). 
Additional patient inclusion and exclusion criteria specific for the coil treatment from 




Table 3: In-and exclusion criteria for coil treatment
In- and exclusion criteria for coil treatment
Inclusion Exclusion
Severe hyperinflation: Total lung 
capacity>100% of predicted, and Residual 
volume>200% of predicted and RV/TLC>58%
Severe hypercapnia (pCO2 >7.5kPa/55 mmHg) 
or hypoxemia (pO2 <6.5kPa/50mmHg)
Post bronchodilator FEV1<45% of predicted Post bronchodilator FEV1<15% of predicted
6 Minute walking distance between 150–450 
meters
DLCO <20% of predicted





- Physically fit/post rehabilitation
- Optimal medication
- Oxygen suppletion when needed
- Bilevel positive airway pressure therapy 
(BiPaP) when needed
Clinically significant bronchiectasis
Severe recurrent respiratory infections 
requiring more than 2 hospitalization stays 
within the past twelve months
COPD exacerbation within 6 weeks before 
treatment
Lung carcinoma or pulmonary nodule on CT 
scan requiring chest CT scan follow-up
Giant bulla of more than one third of the lung 
field on chest CT
Past history of lobectomy, lung volume 
reduction surgery, lung transplantation
Pulmonary hypertension (right ventricular 
systolic pressure >50mmHg on cardiac echo)
Significant congestive heart failure
Alpha-1 antitrypsin deficiency
Anticoagulants that cannot be permanently 
stopped
Allergy to nitinol or one of its components: 
nickel and titanium
RV: residual volume; TLC: total lung capacity; FEV1: forced expiratory volume in 1 second; DLCO: 
diffusing capacity of the lung for carbon monoxide.
 
Long term follow-up & re-treatment with coils
To date, not a lot of data exists on longer term outcome after coil treatment. One 
single center study investigated the safety and efficacy of the coil treatment in the 
long term at 1,2 and 3 years follow-up. At 3-year follow-up, no long-term unexpected 
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adverse and device-related events occurred, with clinical benefit gradually declining 
over time (30).
Re-treatment with coils has been investigated in one pilot study, including 8 patients. 
Re-treatment was performed at a median of 1382 days after initial coil treatment with 
a median additional of 12 coils per patient. The trail was not powered for efficacy 
outcomes. No unexpected adverse events occurred, suggesting feasibility and safety 
of re-treatment (31).
Cost-effectiveness
Cost-effectiveness of the coil treatment has been investigated in the REVOLENS 
trial. Cost was estimated at $47,908 per patient above usual care at 1 year and the 
incremental cost-effectiveness ratio was $782,598 per additional quality-adjusted 
life-year. However, the short duration of the follow-up prevented the authors from 
drawing a conclusion on long term cost-effectiveness, as the financial costs of 
procedure and devices should be allocated over the total duration of clinical benefit. 
Possibly, the expected 5 year follow-up data from this clinical trial will provide more 
insight in cost-effectiveness of the coil treatment (27).
CONCLUSIONS AND FUTURE PERSPECTIVES
Three randomized clinical trials investigating coil treatment have been published 
until now, reporting the results of 452 treated patients up to 12 months after coil 
treatment. In these trials, the coil treatment results in significant improvements 
in pulmonary function and especially quality of life in patients with severe 
hyperinflation.
Since treatment can be performed regardless of collateral ventilation status it may 
be an effective treatment for patients who are not eligible for endobronchial valve 
treatment or other collateral ventilation dependent interventions. In addition, both 
patients with a homogeneous and heterogeneous phenotype can be treated. The 
selection of optimally treated, symptomatic COPD patients with severe emphysema 
and severe hyperinflation while avoiding significant airway disease such as asthma, 
chronic bronchitis and bronchiectasis, is key to achieve treatment success.
Several new studies are currently underway: the first one being the “REACTION study: 
Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial 




non-randomised open label multi-center intervention study. The objectives are to 
gain more knowledge on the mechanism of action, identifying predictors of response 
and describing the effect on patient-based outcomes of endobronchial coil treatment.
A post-marketing study titled “Changes in Lung Physiology and Cardiac Performance 
in Patients With Emphysema Post Bilateral RePneu Coil Treatment” (NCT02499380) is 
aimed at understanding the mechanism of action of the RePneu coil by observing 
changes in lung physiology and cardiac performance in patients treated with RePneu 
coils.
Another study: “LVRC-Micro: Lung Volume Reduction Coil Microbiome Study” 
(NCT03010566), aims to investigate possible changes in the microbiome of the lungs 
in patients 6 months after initial coil treatment.
An overview of current ongoing studies on coil treatment can be found in table 4.
Future research is necessary to provide more insight in different aspects of the coil 
treatment. Whilst studies investigating the mechanism of action of the intervention 
and predictors of response are underway, more work is needed to refine patient 
selection, assess durability of treatment benefit and determine long term cost-
effectiveness.
Table 4: Ongoing studies on lung volume reduction coil treatment
Study title Trial registry number
Endoscopic Lung Volume Reduction Coil Treatment in Patients 
With Chronic Hypercapnic Respiratory Failure
NCT02996149
Improvement of Sleep Quality by RePneu Coils in Advanced 
Pulmonary Emphysema
NCT02399514
Clinical Study to Evaluate the Exercise Capacity in Patients With 
Severe Emphysema Treated With Coils (CYCLONE)
NCT02879331
Post Market Observational, Prospective, Multi-center Study NCT01806636
COPD Co-Pilot AIR Substudy of CLN0014 (Co-Pilot Air) NCT03267992
Lung Volume Reduction Via Coils in Patients With COPD NCT02246569
LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009) 
(RENEW-CROSSOVER)
NCT02059057
Hyperinflation Assessment After Treatment by Lung Volume 
Reduction Coil (HEAT-LVRC)
NCT02835001
NCT: National Clinical Trial Registry Number; COPD: Chronic Obstructive Pulmonary Disease.
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Background: Bronchoscopic lung volume reduction (BLVR) is a valuable treatment 
option for carefully selected patients with severe COPD. There is limited knowledge 
about characteristics and outcomes of patients referred to a specialized center for 
BLVR. The study objectives were to investigate the selection rate for BLVR treatment 
in patients referred for this treatment, and to investigate the differences between 
patients that were selected for BLVR and patients that were not.
Methods: We performed a retrospective analysis of patients with severe COPD who 
were referred to our hospital to assess eligibility for BLVR treatment. Our parameters 
included demographics, comorbidity, chest computed tomography characteristics, 
reasons for rejection from BLVR treatment and patient survival.
Results: In total, 1500 patients were included (mean age 62 years, 50% female and 
forced expiratory volume in 1 second 33% of predicted). Out of this group 282 (19%) 
patients were selected for BLVR treatment. The absence of a suitable target lobe for 
treatment, an unsuitable disease phenotype and insufficient lung hyperinflation 
were the most important factors for not being selected. Patients that were selected 
for any BLVR option lived significantly longer than the group of patients that were 
not selected for BLVR (median 3060 versus 2079 days, P<0.001).
Conclusions: We found that only a small proportion of patients that are referred 
for BLVR treatment is eligible for a BLVR treatment, indicating a need for both better 
referral tools and for the development of new therapies for this group of patients. 
Furthermore, our data suggest that selection for BLVR is associated with a significant 
survival benefit.
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INTRODUCTION
Bronchoscopic lung volume reduction (BLVR) is a valuable treatment option for 
patients with severe COPD and emphysema, aimed at reducing hyperinflation of 
the lung(1). BLVR using endobronchial valves (EBV) and lung volume reduction coils 
(LVRC) have been studied most extensively and demonstrated to be effective, with 
an acceptable safety profile (2).
Dedicated patient selection for BLVR is essential in achieving clinically meaningful 
results after treatment. For example, for the EBV treatment, the absence of interlobar 
collateral ventilation is necessary to achieve successful outcomes and for the LVRC 
treatment superior outcomes are observed in patients with very severe static 
hyperinflation and absence of significant airway disease (3–7).
Several questions on patient selection for BLVR remain unanswered. For example, 
it is unknown what proportion of patients referred for BLVR is potentially eligible 
for any form of BLVR treatment and to our knowledge, this group of patients has 
not been well characterized in the literature. Furthermore, the development of 
new insights in BLVR treatment during this period led to changes in the inclusion 
and exclusion criteria for these treatments which potentially could influence the 
proportion of selected patients.
Therefore, we aimed to investigate 1. which proportion of patients that were referred 
to our hospital were actually selected for BLVR treatment; 2. the differences in 
characteristics and survival between patients that were and were not selected for 
BLVR; 3. to what extent applying updated criteria for eligibility would have affected 
the selection rate.
METHODS
Study design and patient population
We performed a retrospective analysis of the first 1500 patients who were 
consecutively referred to assess eligibility for BLVR treatment between March 2007 
and October 2014, from 62 different hospitals in the Netherlands to our hospital. 
Given the retrospective and anonymous nature of the analyses, this research did not 
fall within the scope of the WMO (Dutch Medical Research with Human Subjects Law) 





Patient selection for BLVR in our hospital starts with the referral of a patient by 
their pulmonary physician. Referring physicians are requested to include recent 
lung function results (spirometry and body plethysmography), chest computed 
tomography (HRCT) scan, and a complete medical history in their referrals. During 
a multidisciplinary team meeting, a first selection is made. Potential BLVR candidates 
are invited to our hospital for a consultation with an interventional pulmonologist.
Treatment
Patients that were eligible for BLVR treatment were included in clinical trials 
investigating EBV (3,8–11), LVRC (12–15), polymeric lung volume reduction(16), 
pneumostoma (17–19) and airway bypass stents (20) or in our regular EBV treatment 
programme (BREATH-NL: NCT02815683).
Outcomes
The primary outcome of this study was the selection rate for BLVR treatment. 
Secondary outcomes were derived from the referral documentation and included: 
demographics, lung function (spirometry and body plethysmography), smoking 
status, oxygen therapy use and maintenance anticoagulant use. Furthermore, the 
medical history of all patients was screened for a selection of comorbidities. All 
available CT-scans were visually reviewed and assessed by JBAW for the presence 
of specific characteristics, these assessments were supervised by DJS.
The degree of emphysema destruction was scored on a 0 to 4 qualitative Likert scale 
with higher scores indicating more emphysematous destruction (figure 1) (21,22). In 
case of ineligibility for BLVR, we reported the reasons why patients were found not 
to be eligible for treatment. The survival status of the referred patients was verified 
with the Dutch government (Personal Records Database) on June 16th 2019.
Figure 1: Qualitative scale of emphysematous destruction, scored on a 0 to 4 scale with higher scores indicating 
more emphysematous destruction.
43
 Patient selection for bronchoscopic lung volume reduction
Theoretical model
We applied some of the most recent inclusion and exclusion criteria for EBV and 
LVRC, according to the guidelines (1), on our cohort to assess the proportion of 
patients eligible for these treatments and whether this proportion was different 
from the proportion of patients actually selected for these treatments. The criteria 
applied for EBV treatment included forced expiratory volume in 1 second (FEV1) 
between 20 and 50% of predicted, residual volume (RV) ≥175% of predicted, RV/
total lung capacity (TLC) ratio of ≥0.58, visually intact major fissure (left or right) and 
emphysema destruction ≥2 on destruction scale (figure 1).
The criteria applied for LVRC included FEV1 between 20 and 50% of predicted, RV 
≥200% of predicted, RV/TLC ratio of ≥0.58 and emphysema destruction ≥2 on the 
destruction scale (figure 1).
Statistical analysis
Differences in patient characteristics between the group that was selected for 
treatment and the group that was not, were analysed using an Independent-Samples 
T-test in case of normal distribution of data and a Mann-Whitney-U test in case of 
non-normal distribution. A Chi-squared test was used in case of categorical data. 
Due to the explorative nature of the CT data, only demographic data are presented 
and no statistical analysis were performed. Survival time was defined as the time 
after the date of discussion in the multidisciplinary team meeting until the date of 
verification with the Dutch government. Survival was analysed using the Kaplan-
Meier method. Comparison in survival between the groups selected or not selected 
for treatment was performed using the Mantel-Cox log-rank test and comparison in 
survival between EBV and LVRC treatment was performed using Breslow’s test. All 
statistical analyses were performed using SPSS version 23 (IBM, New York, NY, USA). 
P-values <0.05 were considered statistically significant.
RESULTS
In total, 1500 patients (50% female) were included in our analysis, with a mean age 
of 62 years and FEV1 of 33±14% of predicted (additional patient characteristics are 
shown in table 1). From this group, 651 patients (43%) were invited for a consultation 
in our hospital. Of the total referred population 282 (19%) patients were selected for 
a clinical trial or regular treatment programme and therefore a total of 1218 (81%) 




Out of the group of 282 patients that were selected for a bronchoscopic treatment, 
175 patients (62%) were selected for EBV, 93 patients (33%) for LVRC, 3 patients (0.2%) 
for airway bypass stents, 9 patients (3%) for polymeric lung volume reduction and 
2 patients (0.1%) for a pneumostoma.
Figure 2: Study flowchart. PLVR: Polymeric lung volume reduction.
 
Patients selected for BLVR were significantly younger (59 versus 63 years), had a lower 
FEV1 (28% versus 34% of predicted) and a higher RV (237% versus 215% of predicted) 
compared to the group of patients not selected for BLVR (all P<0.001).
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Number of patients 1500 282 1218
Age (years) 62±9 59±8 63±9 P<0.001
Female (%) 750 (50%) 179 (63%) 571 (47%) P<0.001
BMI (kg/m2) 24±5 24±4 24±5 P=0.02
Pack-years (years) 38±18 36±16 38±18 P=0.18
FEV1 (L) 0.9±0.5 0.8±0.3 1.0±0.5 P<0.001
FEV1predicted (%) 33±14 28±8 34±15 P<0.001
FVC (L) 2.8±1.0 2.6±0.9 2.8±1.0 P=0.01
FVCpredicted (%) 79±21 77±19 79±22 P=0.08
RV (L) 4.8±1.3 4.9±1.1 4.7±1.3 P=0.03
RVpredicted (%) 219±56 237±46 215±58 P<0.001
TLC (L) 7.8±1.6 7.8±1.5 7.8±1.6 P=0.77





















Oxygen therapy 418 (28%) 80 (28%) 338 (28%) P=0.84
Maintenance anticoagulant use 280 (19%) 44 (16%) 236 (19%) P=0.14
Participation in previous pulmonary 
rehabilitation or weekly physiotherapy
684 (46%) 174 (62%) 510 (42%) P<0.001
Weekly physiotherapy 567 (38% 168 (60%) 399 (33%) P<0.001
Data are presented as number of patients (%), mean ± standard deviation or percentage of the 
predicted value ± standard deviation. BMI: Body mass index; FEV1: forced expiratory volume in 
1 second; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity. Differences in 
patient characteristics between the selected and not selected group for treatment was analysed 
using a 2-samples T-test or Chi-square test.
The most frequently encountered reasons for ineligibility for BLVR treatment were: 
absence of a suitable target lobe for treatment (18%), unsuitable disease phenotype 
for treatment (chronic bronchitis, frequent exacerbations, asthma) (18%) and 





The CT scans of 1211 patients (81%) could be assessed, for 289 patients assessment 
was not possible because of scan unavailability or insufficient image quality for 
assessment. The proportion of patients with a homogeneous and heterogeneous 
distribution of emphysema was similar (52% versus 48%). Upper lobe predominant 
emphysema was observed more often than lower lobe predominant emphysema 
(71% versus 29%). The left major fissure was found to be visually intact in 44% of 
patients, the right major in 25% of patients and the right minor fissure in 12% of 
patients (see table 3).
Table 4 displays the reported comorbidities. Patients referred for BLVR had an 
average of 1.4 comorbidities and the most frequently encountered comorbidities 
were hypertension (22%), confirmed or suspected asthma (18%) and coronary 
artery disease (10%). Patients selected for BLVR had significantly less comorbidities 
compared to the group of patients not selected for BLVR (1.1 versus 1.4, P<0.01).
The survival status of 1272 patients (85%) could be verified. The overall median 
survival was 2316 days (95%CI: 2146-2485 days). The median follow-up was 2351 
days (95%CI: 2451-2514 days). Patients that were referred to our hospital but were 
not invited for consultation had a median survival of 1808 days (95%CI: 1622-
1994) and patients who were invited for consultation but who were not selected 
for treatment had a median survival of 2524 days (95%CI: 2234-2814). Patients 
that were selected for BLVR lived significantly longer than the group of patients 
that was not selected for BLVR (median 3060 versus 2079 days, P<0.001), see 
figure 3. No significant survival difference was observed between patients who 
were selected for EBV treatment and those who were selected for LVRC (P=0.45). 
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Table 2: Contraindications in patients not selected for BLVR
Contraindication Prevalence
Number of patients 1218
Number of contraindications




Absence of suitable target lobe for treatment 221 (18%)
Unsuitable disease phenotype (chronic bronchitis, frequent exacerbations, asthma) 219 (18%)
Insufficient hyperinflation of the lungs 197 (16%)
Presence of comorbidity 162 (13%)
Homogeneous distribution of emphysema 125 (10%)
Incomplete interlobar fissures 109 (9%)
Patient renounced treatment 95 (8%)
Pulmonary function testing outcomes not meeting minimum hyperinflation and/or 
airway obstruction requirements
95 (8%)
No trial available at moment of evaluation 94 (8%)
Low degree of emphysema destruction 83 (7%)
Did not stop smoking for >6 months 79 (7%)
Did not yet participate in pulmonary rehabilitation 73 (6%)
Maintenance anticoagulant use 54 (5%)
Too high degree of emphysema destruction 53 (4%)
Presence of bullae 47 (4%)
Paraseptal emphysema phenotype 47 (4%)
High level of exercise capacity 43 (4%)
Suspicious nodules in the lung that require follow-up 38 (3%)
Too poor condition for treatment 35 (3%)
Prior thoracic surgery 31 (3%)
Body mass index too high or too low 26 (2%)
Pulmonary Hypertension 22 (2%)
Alpha-1 antitrypsin deficiency 15 (1%)
Lung transplanted before BLVR treatment 3 (0.2%)
Data are presented as number of contraindications (percentage of patients with 





Table 3: CT Characteristics




Number of patients 1500 282 1218





















Distribution homogeneous/heterogeneous (%) 48/52 31/69 53/47
Upper/lower lobes predominant (%) 71/29 64/36 75/25
Destruction LUL 1/2/3/4 (%) 40/38/19/2 35/46/19/1 42/35/19/3
Destruction LLL 1/2/3/4 (%) 55/31/11/1 52/33/13/2 56/31/10/1
Destruction RUL 1/2/3/4 (%) 37/35/24/3 33/39/26/2 38/34/23/3
Destruction RLL 1/2/3/4 (%) 56/32/10/1 53/32/13/2 56/31/9/1
Left major fissure 
(intact/>90%intact/<90%intact/unknown (%)
44/26/29/2 58/20/22/0 40/28/31/2
Right major fissure 
(intact/>90% intact/<90% intact/unknown (%)
25/32/41/1 36/31/33/0 22/33/44/2
Right minor fissure
(intact/>90% intact/<90% intact/unknown (%)
12/14/72/3 12/18/70/0 11/13/72/3









Giant bullae 195 (16%) 21 (8%) 174 (19%)
Nodules requiring follow up 89 (7%) 27 (10%) 62 (7%)
Fibrosis 23 (2%) 2 (0.7%) 21 (2%)
Pleural pathology 13 (1%) 2 (0.7%) 11 (1%)
Suspect for pulmonary hypertension 148 (12%) 25 (9%) 123 (13%)
Data is presented as number of patients (percentage of patients) or as percentage of cases. CT: 
computed tomography; LUL: left upper lobe; LLL: left lower lobe; RUL: right upper lobe; RLL: right 
lower lobe. Destruction score based on a 1 to 4 Likert scale, with higher scores indicating more 
severe emphysematous destruction.
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Table 4: Comorbidities reported in the referral documentation
Comorbidity All referrals Selected for 
treatment
Not selected for 
treatment
Number of patients 1500 282 1218









Hypertension 323 (22%) 72 (26%) 251 (21%)
Confirmed or suspected asthma 270 (18%) 58 (21%) 212 (17%)
Coronary artery disease 153 (10%) 16 (6%) 137 (11%)
Dyslipidemia 117 (8%) 20 (7%) 97 (8%)
Diabetes 112 (8%) 15 (5%) 97 (8%)
Osteoporosis 105 (7%) 19 (7%) 86 (7%)
Obesity (BMI>30) 105 (7%) 12 (4%) 93 (8%)
Atrial fibrillation 84 (6%) 4 (1%) 80 (7%)
Myocardial infarction 82 (6%) 6 (2%) 76 (6%)
Cerebrovascular incident 76 (5%) 12 (4%) 64 (5%)
Alpha-1 antitrypsin deficiency 70 (5%) 16 (6%) 54 (4%)
Peripheral artery disease 59 (4%) 6 (2%) 53 (4%)
Heart Failure 54 (4%) 5 (2%) 49 (4%)
Depression 54 (4%) 11 (4%) 43 (4%)
Pulmonary embolus 48 (3%) 10 (4%) 38 (3%)
Pulmonary hypertension 46 (3%) 1 (0.4%) 45 (4%)
Gastro-oesophageal reflux disease 43 (3%) 7 (3%) 36 (3%)
Degenerative joint disease 38 (3%) 4 (1%) 34 (3%)
Anxiety 35 (2%) 7 (3%) 28 (2%)
Obstructive sleep apnea syndrome 33 (2%) 5 (2%) 28 (2%)
Gastric ulcer 24 (2%) 2 (1%) 22 (2%)
Pulmonary malignancy 21 (1%) 2 (1%) 19 (2%)
Anemia 20 (1%) 0 (0%) 20 (2%)
Chronic kidney disease 15 (1%) 0 (0%) 15 (1%)
Pulmonary fibrosis 10 (0.7%) 0 (0%) 10 (0.8%)
Liver cirrhosis 2 (0.1%) 1 (0.4%) 1 (0.1%)
Data are presented as number of patients (percentage of patients), mean ± standard deviation 
or median (range). Differences in the number of comorbidities were assessed using Mann-




Figure 3: Kaplan Meier plots of survival. Plot A: Survival of the patients that were selected for treatment and 
the patients that were not selected for treatment. Plot B: Survival of the patients that were selected for EBV, 
selected for LVRC, invited to our hospital for consultation but not selected for BLVR, not selected for BLVR and 
not invited to our hospital for consultation. EBV: endobronchial valve treatment; LVRC: lung volume reduction 
coil treatment; BLVR: bronchoscopic lung volume reduction; MDT: multidisciplinary team meeting.
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Theoretical model
When applying some of the currently established inclusion and exclusion criteria 
for endobronchial valve treatment and lung volume reduction treatment, we 
identified 283 patients eligible for EBV treatment (19%) while 175 patients (12%) 
were actually selected for EBV in this cohort and 144 patients (10%) would currently 
be eligible for LVRC while 93 patients (6%) were actually selected for LVRC (figure 4). 
Figure 4: Eligibility for EBV and LVRC after application of current inclusion and exclusion criteria. Panel A: 
Eligible patients for EBV treatment. Panel B: Eligible patients for LVRC treatment. N: number of patients; FEV1: 
forced expiratory volume in 1 second; RV: residual volume; TLC: total lung capacity; EBV: endobronchial valve 
treatment; LUL: left upper lobe; RUL: right upper lobe; LLL: left lower lobe; RLL: right lower lobe; LVRC: lung 





Only one out of five patients who were referred for BLVR treatment to our hospital 
were selected for BLVR treatment. Ineligibility for BLVR treatment was most often 
caused by: the absence of a suitable target lobe for treatment, an unsuitable disease 
phenotype for treatment and insufficient lung hyperinflation. Overall survival in the 
group of patients referred for BLVR was poor with a median survival of approximately 
6 years.
To our knowledge, this is the largest study investigating patients referred for BLVR 
eligibility assessment. In a recent study by Polke et al, who studied patients that 
were referred to a BLVR expert center in Heidelberg (Germany), a higher proportion 
of patients were found to be eligible for BLVR treatment, possibly caused by a more 
strict preselection of patients for referral (23). The same study also found the absence 
of a suitable target lobe to be the most frequent contra-indication for BLVR, which 
is in line with the results of our study (23).
Only a small proportion of the already preselected group of patients that were 
considered to be eligible for BLVR by the referring physician is selected for BLVR 
treatment. This highlights both the need for improved referral strategies on the 
one hand, and the important need for additional therapeutic options for patients 
with severe COPD on the other hand. Alternative interventions for BLVR include 
lung volume reduction surgery or lung transplantation, however both treatments 
suffer from huge limitations related to the invasiveness of the procedure, scarce 
availability and strict selection procedures. Patients with a severe chronic bronchitis 
phenotype of COPD are a common example of an unsuitable disease phenotype for 
BLVR. Both endobronchial treatment with liquid nitrogen cryospray and targeted 
lung denervation are currently under development for this phenotype. Liquid 
nitrogen cryospray is a treatment aimed at inducing an airway tissue healing effect 
by destroying the hyperplastic goblet cells and excess submucous glands (24). 
Target lung denervation is a treatment designed to decrease airway resistance 
and mucus hyper section, by inhibiting parasympathetic pulmonary nerves, using 
radiofrequency ablation therapy (25).
New insights in BLVR treatment caused inclusion and exclusion criteria for these 
treatments to change over time, which might have affected the proportion of 
patients considered eligible for BVLR. For example, a previous contra-indication for 
EBV trials included the presence of alpha-1 antitrypsin deficiency, but these patients 
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are now considered eligible for treatment (3,26). When we applied the most recent 
inclusion and exclusion criteria on our cohort, we observed a discrepancy between 
the number of patients that were eligible for treatment and those who were actually 
selected for treatment. This could be the result of the fact that not all treatments 
were available at all times during the time frame of this study, the clinical trial context 
with strict in and exclusion criteria or because we applied only a selection of the 
most stringent criteria in our model.
A significant survival benefit was observed for the group of patients that was 
selected for BLVR treatment, when compared to the group that was not selected 
for treatment. This survival benefit was already observed in several previous 
studies which demonstrated that when successful lobar atelectasis is achieved 
after EBV treatment, patients have a substantial, persisting survival benefit (27–29). 
Structural survival data for the LVRC treatment is not yet available. We acknowledge 
that the survival benefit observed in the group of patients that were selected for 
treatment might have not only been due to a direct result of the actual intervention 
but also caused by the exclusion of patients that were too frail, due to any cause, 
for treatment. On the other hand, both the degree of hyperinflation and airway 
obstruction were higher in the group selected for treatment, suggesting selection of 
patients with severe disease for treatment. In addition, given that most treatments in 
this cohort took place in the early phase of the development of these treatments, the 
current data might actually underestimate the survival benefit of these treatments.
Patient selected for BLVR had significantly less comorbidities than patients who 
were not selected for BLVR. On average, the referred patients had more than one 
comorbidity. However, this was still lower than in a study by Putcha et al, possibly 
caused by the underreporting of comorbidities by the referring physicians in 
our cohort or because of the fact that the referring physicians already referred a 
preselected population due to study selection criteria on comorbidity (30,31).
We assessed the CT characteristics of the referred patients and found the left major 
fissure to be most often intact on the CT scans of the referred patients, followed 
by the right major fissure and the right minor fissure. The proportion of visually 
intact fissures was in line with previously published data on this topic, and also in 
agreement with the latest clinical trials investigating EBV and intrabronchial valves, 
in which the left upper and left lower lobe were selected for treatment in more than 




This study has several limitations: first of all, our population is representative of 
the group of patients referred to a BLVR center but not of the total population of 
patients with severe emphysema, and can therefore not serve to accurately assess 
the proportion of eligible patients for BLVR in the total population of patients with 
emphysema. Secondly, inherent to the retrospective nature of this study, we had to 
rely on the quality of the referral documentation from other hospitals. Incomplete or 
incorrect referral documentation might have especially affected the data presented 
on comorbidity, which was based on the medical history included in the referral 
documentation, probably leading to an underestimation of comorbidity (31). 
Thirdly, the CT scans were of very different quality and settings, because referral 
material was used, making a preferred quantitative assessment not possible (34). 
These scans were assessed by one reviewer only (JBAW), under supervision of one 
of the authors (DJS), a task that in an ideal setting would have been performed by 
a panel of reviewers. Fourthly, since these were the first 1500 BLVR referrals sent to 
our hospital, most patients were treated in a clinical trial context, which probably 
led to a more strict selection compared to treatment outside clinical trial context, 
underestimating the number of patients eligible for BLVR treatment. Fifthly, it would 
have been of additional value to include a survival prediction index like BODE, but 
we did not have the necessary data available to perform this (35).
A strength of our study is the large number of patients that were included in this 
retrospective study. Another strength of our study is the fact that we were able to 
verify the survival status of our patients with the Dutch government, which increased 
the reliability of our survival data.
Future research might include the development of a model that is able to predict 
the à priori chances of BLVR eligibility. Such a model could assist both physicians 
and patients in deciding whether referral to a BLVR centre is indicated. Indeed, the 
right patient should be referred for the right treatment, to improve efficiency and 
avoid the burden for the patient. Future research is needed to identify the size of 
the potential pool of patients eligible for BLVR treatment as a previous study by 
Pietzsch et al suggested that BLVR currently is only used in a small proportion of 
patients with severe emphysema (36).
In conclusion, we found that only a small proportion of patients that are referred for 
BLVR treatment is eligible for a BLVR treatment, indicating a need for the development 
of new therapies for this group of patients and better referral tools. Furthermore, our 
data suggest that selection for BLVR is associated with a significant survival benefit.
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Significant differences in body plethysmography 
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Background: During the evaluation of potential bronchoscopic lung volume 
reduction (BLVR) candidates in our hospital, we frequently observe patients with a 
lower residual volume (RV) value compared to the value measured in their referring 
hospital, although both measured by body plethysmography. We explored to what 
degree RV and other pulmonary function measurements match between referring 
hospitals and our hospital.
Methods & Results: We retrospectively analysed a total of 300 patients with severe 
emphysema (38% male, median age 62 years (range 38-81), median forced expiratory 
volume in 1 second 29% (range 14-65) of predicted and a median of 40 packyears 
(range 2-125)). We measured a median RV of 4.47 liter (range 1.70-7.57), which was 
a median 310ml lower than in the referring hospitals (range -3.04 - +1.94), P<0.001).
Conclusions: In conclusion, this retrospective analysis demonstrated differences in 
RV measurements between different hospitals in patients with severe emphysema. 
Overestimation of RV can lead to unnecessary referrals for BLVR and potential 
treatment failures. To avoid disappointment and unnecessary hospital visits, it is 
important that body plethysmography measurements are accurately performed by 
applying preferably the unlinked method in these patients.
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INTRODUCTION
Bronchoscopic lung volume reduction (BLVR) is a valid treatment option for selected 
patients with severe emphysema (1,2). Besides having significant emphysema, 
the key selection criterion for this treatment is the presence of severe static lung 
hyperinflation, defined as residual volume (RV) of >175% of the predicted value (3). 
Measuring RV can be performed using body plethysmography, helium gas dilution, 
nitrogen washout and quantification of lung volumes on a thoracic CT scan, but 
all can be technically challenging (4). In patients with severe emphysema, body 
plethysmography is the preferred method to measure RV, as gas dilution techniques 
tend to underestimate lung volumes in patients with obstructive lung disease and 
as CT scan imaging needs full expiration, which is difficult to accurately monitor in 
the radiology lab (5).
During the evaluation of potential BLVR candidates in our hospital, a BLVR expert 
center, we frequently observe patients with a lower RV value compared to the 
value measured in their referring hospital, although both measured by body 
plethysmography. When the RV value is too low for BLVR treatment, this may lead 
to disappointment of patients and their caregivers, together with unnecessary, time-
consuming and expensive hospital visits, and even wrong treatment selection. We 
therefore explored to what degree RV and other pulmonary function measurements 
match between referring hospitals and our hospital, where we strictly adhere to the 
published guidelines.
METHODS
Using a retrospective analysis we included patients with severe emphysema who 
were referred from 62 different hospitals in the Netherlands to our hospital for BLVR 
evaluation between June 2012 and September 2017. Patients who had both body 
plethysmography and spirometry measurements available in their referring hospital 
as well as in our hospital, within an interval of less than one year between these 
measurements were included. In our hospital, spirometry and body plethysmography 
(MasterScreen™, Vyaire Medical, Mettawa, USA) were performed according to the 
American Thoracic Society (ATS)/European Respiratory Society (ERS) standards (4,6). 
The equipment and guidelines used in the referring hospitals were unknown. Data 
is presented as median (range). Differences in lung function outcomes between 
referring hospitals and our hospital was analyzed with a Wilcoxon Signed Rank test. 




referring hospitals and our hospital was assessed using Spearman’s rho. This analysis 
was part of a study which was approved by our local medical ethics committee. The 
study was conducted in accordance with the Declaration of Helsinki.
RESULTS
A total of 300 patients with severe emphysema (38% male, median age 62 years 
(range 38-81), median forced expiratory volume in 1 second (FEV1) 29% (range 14-65) 
of predicted and a median of 40 packyears (range 2-125)) were included.
We measured a median RV of 4.47 liter (range 1.70-7.57), which was a median 310ml 
lower than in the referring hospitals (range -3.04 - +1.94), P<0.001). Furthermore, we 
observed significantly higher vital capacity (VC), lower total lung capacity (TLC) and 
lower intrathoracic gas volume (ITGV) than the referring hospitals (table 1).
Median time between RV measurements was 118 days (23-364). There was no 
correlation between differences in RV and time between both measurements 
(Spearman’s rho=0.06, P=0.29).
Of the patients with an RV higher than 175% of predicted in their referring hospital, 
34 patients (11%) were not accepted for BLVR treatment due to an RV less than 
175% of predicted when re-measured in our hospital. In addition, 133 out of 300 
(44%) patients had a larger difference in RV between hospitals than the established 
minimal important difference (MID) (>400ml decrease) (7). In comparison, 30 out of 
300 (10%) patients had a lower RV in the referring hospital, compared to our hospital 
that was larger than the MID.
A selection of patients (n=82) underwent a second body plethysmography 
measurement in our hospital within one year (often for clinical trial purposes), with 
a median time between measurements of 69 days (7-352). There was no significant 
difference between the two RV measurements within our hospital (median difference 
0.07 liter (P=0.43)).
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Table 1: Pulmonary function outcomes
N Referring Hospitals Our hospital Median Difference P-Value
RV (liter) 300 4.84 (1.75-9.89) 4.47 (1.70-7.57) 0.31 (-3.04-1.94) P<0.001
RV%pred (%) 299 224 (98-392) 212 (107-350) 15 (-119-171) P<0.001
TLC (liter) 297 7.58 (4.19-12.7) 7.47 (4.21-12.1) 0.11 (-2.63-4.69) P<0.001
RV/TLC (ratio) 297 0.63 (0.40-0.87) 0.59 (0.34-0.80) 0.04 (-0.34-0.14) P<0.001
VC (liter) 281 2.75 (1.11-6.46) 3.02 (1.46-6.77) 0.20 (-1.18-3.65) P<0.001
ITGV (liter) 257 5.71 (1.74-11.0) 5.63 (2.41-10.2) 0.07 (-3.11-3.03) P=0.01
FEV1 (liter) 298 0.81(0.34-2.17) 0.82 (0.35-2.50) 0.01 (-0.64-1.25) P=0.10
FEV1%pred (%) 298 29 (14-65) 31 (15-73) 0.87 (-17-35) P<0.01
Data are presented as median (range). N: number of patients; RV: residual volume; %pred: 
percentage of predicted; VC: vital capacity; TLC: total lung capacity; ITGV: intra thoracic gas 
volume; FEV1: forced expiratory volume in 1 second. Differences between referring hospitals and 
our hospital was analyzed with a Wilcoxon Signed Rank test.
DISCUSSION
Eleven percent of patients who were referred for treatment were directly excluded 
from BLVR treatment because of lower RV outcomes in our hospital. Our findings are 
in line with previous research performed in children by Paton et al., who compared 
spirometry and plethysmography outcomes between different hospitals and also 
found significant differences in RV and TLC even after standardization of procedures 
and equipment between hospitals without finding a significant difference in 
spirometry outcomes (8).
There are several possible explanations for the between hospital differences in RV. 
Different body plethysmography measurement techniques could have been applied. 
This is supported by statistically significant differences in both VC as well as ITGV 
outcomes between our hospital and the referral hospitals. Different approaches 
could be the use of linked versus unlinked VC manoeuvres (9). Potentially, time 
between measurements and thus progression of disease could have led to the 
difference between RV outcomes, but this would result in an increase of RV instead 
of a decrease. We did not find a significant association between time between 
measurements and RV. A selection of patients (n=82) underwent a second body 
plethysmography measurement in our hospital just before BLVR treatment. There 
was no significant difference in absolute RV outcome within an interval of 1 year, 




We applied an RV 175% of predicted threshold for BLVR eligibility, which was 
based on the 2019 BLVR expert panel recommendations and in line with the latest 
published clinical trial investigating EBV treatment (LIBERATE)(10,11).
This study has several limitations. First, an arbitrary maximum interval of 1 year 
between two plethysmography measurements was used, however when using a 
6 months interval, absolute RV between hospitals was still significantly different 
(P<0.001, n=222). Secondly, we were not aware of patient conditions when they 
performed the measurement in their referring hospital, which could have influenced 
RV outcomes. Possibly, body plethysmography measurements in referring 
hospitals were performed during exacerbations of disease, leading to higher RV 
outcomes in the referring hospitals (12,13). Thirdly, we could not verify that all 
body plethysmography measurements in the referring hospitals were performed 
after bronchodilator administration and we were unaware of the guidelines and 
equipment used. Fourthly, even though the application of the unlinked method 
probably resulted in lower RV outcomes in our hospital, compared to the referring 
hospitals, we did not have data available supporting improved patient outcomes 
after BLVR as a consequence of this technique.
Based on our clinical experience, we have the following suggestions to reduce 
overestimation of RV in severe emphysema patients during body plethysmography 
measurement. First, the pulmonary function technician who performs the 
measurement should take a considerate amount of time to ensure that patients 
achieve a full expiration state when performing the ERV manoeuvre during the 
inspiratory VC measurement. Secondly, the presence of dynamic hyperinflation 
should be prevented by reducing physical effort just before measurement as well 
as allowing the patient to get off the mouthpiece between manoeuvres (14). Thirdly, 
we suggest the use of the unlinked manoeuver. This means that directly after the 
ITGV manoeuver, the IC measurement will be performed and that the maximum VC 
measured during spirometry is used for the calculation of RV. Particularly for patients 
with severe emphysema, it is difficult to perform a maximal VC manoeuver directly 
after the ITGV manoeuver, resulting in an underestimation of VC and therefore an 
overestimation of RV. Finally, we suggest that the measurement is performed in a 
stable state after optimal bronchodilation.
The estimation of lung volumes using quantitative CT analysis could become a 
valuable tool in the future (15). However this method relies heavily on both the 
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quality of the analyzed scans as well as reaching a full in- and expiration state during 
scanning.
In conclusion, this retrospective analysis demonstrated differences in RV 
measurements between different hospitals in patients with severe emphysema. 
Overestimation of RV can lead to unnecessary referrals for BLVR and potential 
treatment failures. To avoid disappointment and unnecessary hospital visits, it is 
important that body plethysmography measurements are accurately performed by 
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Background: Adequate target lobe selection for endobronchial valve (EBV) 
treatment in patients with severe emphysema is essential for treatment success 
and can be based on emphysema destruction, lobar perfusion, lobar volume and 
collateral ventilation. As some patients have more than one target lobe for EBV 
treatment we were interested whether we could identify the least functional lobe.
Objective: The objective of this study was to investigate the relationship between 
endoscopic lobar measurement of oxygen uptake, lobar destruction and vascular 
volume and whether this could help in identifying the least functional lobe and thus 
optimal target for EBV treatment.
Methods: We prospectively included patients who were scheduled for EBV treatment 
in our hospital. A customized gas analysis set-up was used to measure lobar O2 
uptake after lobar balloon occlusion. Quantitative CT analysis was performed to 
assess degree of emphysematous destruction and lobar arterial and venous volumes.
Results: Twenty-one (5 male/16 female) patients with emphysema (median age 63 
years, FEV1 25% of predicted, residual volume 234% of predicted) were included and 
49 endoscopic lobar measurements were performed. A lower O2 uptake significantly 
correlated with a higher degree of emphysematous lobar destruction (Spearman’s 
rho: 0.39, P<0.01), and with a lower arterial and venous vascular volumes of the lobes 
(respectively -0.46 and -0.47, both P<0.001).
Conclusions: Endoscopic measurement of lobar O2 uptake is feasible in patients with 
emphysema. Measurement of lobar O2 uptake helped to identify the least functional 
lobe and can be used as additional tool for EBV target lobe selection.
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INTRODUCTION
Endobronchial valve (EBV) treatment is a minor invasive and effective bronchoscopic 
lung volume reduction treatment in selected patients with severe emphysema 
(1–4). The purpose of EBV treatment is to induce lobar atelectasis by occluding all 
segmental bronchi of a destructed and hyperinflated lobe with one-way valves (5). 
Patient selection is essential for EBV treatment success and important selection 
criteria are the presence of a suitable emphysematous target lobe with absence 
of collateral ventilation (CV), the degree of lung hyperinflation and absence 
of significant comorbidity (5). Target lobe selection is based on the degree of 
emphysema destruction, absence of collateral ventilation (CV), lobar volume of 
the target lobe and ipsilateral lobe, low lobar perfusion assessed using perfusion 
scintigraphy and absence of pleural adhesions (6–8).
Some patients have more than one suitable target lobe for EBV treatment. 
Quantitative CT analysis may help to identify the most suitable target lobe for 
treatment. In addition to quantitative CT analysis, perfusion scintigraphy may also 
help to identify the target lobe in these patients, preferably targeting the lobe with 
the lowest perfusion (9). However, in our hospital we encounter patients who after 
applying all available diagnostic techniques, still have more than one target lobe 
eligible for EBV treatment.
Freitag et al. previously demonstrated the use of endoscopic capnometry and 
oximetry curves to improve EBV target zone identification (10). Building on this 
approach, we wanted to investigate whether the quantification of lobar oxygen 
(O2) uptake capacity might help identifying the least functional lobe, and therefore 
best target lobe for EBV treatment.
The objective of this study was to investigate the relationship between endoscopic 
lobar measurement of oxygen uptake, lobar destruction and vascular volume and 
whether this could help in identifying the least functional lobe and thus optimal 






In this prospective feasibility study we included patients with severe emphysema 
who were scheduled for EBV treatment in a national treatment registry (BREATH-NL: 
NCT02815683), in our hospital from February 2018 to May 2018. All patients provided 
written informed consent for the treatment procedure, flow measurements, and 
data collection.
Outcomes
The primary outcome of this study was the association between the degree of lobar 
emphysematous destruction and O2 uptake capacity.
Secondary, we wanted to investigate the association of the uptake capacity of O2 
in the measured lobes with the vascular quantitative CT (QCT) parameters: arterial 
and venous volumes of the lobes. Furthermore, the association between lobar 
emphysematous destruction and arterial and venous volume of the lobes was 
assessed.
Equipment
Endoscopic O2 concentration measurements were performed using a customized 
set up. An ISA® sidestream gas analyser (Masimo AB, Danderyd, Sweden) was used, 
sampling air at 50ml per minute and collecting data 20 times per second (10). To 
achieve lobar isolation, a Chartis® catheter (Pulmonx Inc., Redwood City, CA, USA) 
was used. The Chartis catheter is equipped with an inflatable balloon tip and can be 
advanced through the working channel of a flexible bronchoscope (6). A Nomoline® 
sampling line (200cm) (Masimo AB) was used to prevent moisture from disturbing the 
gas measurements. The sampling delay caused by the length of the Chartis catheter 
and Nomoline was approximately 2 seconds. A Tangent® console (Burlingame, USA) 
running customized software (Pulmonx Inc. Redwood City, CA, USA) was used to 
allow characterization and live visualization of data during the measurements, as 
well as data extraction after the procedure. An overview of the measurement set 
up can be found in figure 1.
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Figure 1: Schematic representation of the measurement set-up demonstrating occlusion of the left upper lobe.
Measurement
The presence of interlobar collateral ventilation was assessed in every patient using 
the Chartis measurement. After the Chartis measurement, the entrance of the lobe 
selected for measurement was occluded by inflating the balloon of the Chartis 
catheter again, effectively isolating this lobe for 2 minutes. Directly after occlusion 
the O2 uptake measurement was started by measuring the oxygen concentration 
distal of the inflated balloon. Measurements were performed in at least the EBV 
treatment target lobe as well as the adjacent lobe. The right middle lobe was 
excluded from measurement.
Measurements were only included for analysis when absence of CV was confirmed 
by Chartis and a reliable gas concentration signal was obtained. Measurements were 
excluded from analysis when total airway collapse occurred, when mucus occluded 
the catheter distorting the measurements or when the balloon occlusion of the 
airway was lost during measurement.
Measurements (as well as Chartis and the EBV procedure) were performed under 
general anesthesia. Patients were intubated with a flexible 9 mm endotracheal tube. 
The primary ventilator settings were: volume controlled ventilation mode with 
target settings of low ventilation frequency (8–10 times per minute), tidal volumes 
4-6ml/kg, fixed fraction of inspired oxygen (FiO2) of 50%, long expiratory settings 






Lobar emphysematous destruction and lobar volumes were determined using 
the StratX® QCT platform (Pulmonx, Inc, Redwood City, CA, USA). The assessment 
of arterial and venous volume per lobe was performed using Thirona Lung 
Quantification software® (Thirona, Nijmegen, Netherlands) (see figure 2).
 
Figure 2: Quantitative CT analysis of arterial and venous volume. Plot A: Sagittal view of the left lung with left 
lower lobe predominant emphysema. Plot B: 2D artery-vein overlay of the left lung with decreased vascular 
volume in the left lower lobe. Plot C: 3D artery-vein rendering of the left lung.
Statistical analysis
Linear regression was performed to quantify O2 uptake capacity with O2 
concentration as a dependent variable and measurement duration as independent 
variable. Slope coefficients were derived of O2 uptake capacity (change in %O2 per 
second) for each measurement.
Spearman’s rho was used to test the association between O2 uptake capacity and 
lobar emphysematous destruction (percentage of voxels less than -950 Hounsfield 
units), the association between O2 uptake capacity and arterial or venous volume in 
the measured lobes, the association between arterial and venous volume and lobar 
emphysematous destruction and the association between O2 uptake capacity and 
lobar volume. P-values <0.05 were considered significant. Statistical analyses were 
performed using SPSS version 23 (IBM, New York, NY, USA).
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RESULTS
Patients
Twenty-one patients were included with a median age of 63 years (range 39-73), 
24% male and a forced expiratory volume in one second (FEV1) of 25% of predicted 
(range 13-39). Patient characteristics can be found in table 1.




Age (years) 63 (39-73)
BMI (kg/m2) 23 (19-35)
Pack-years (years) 40 (9-147)
FEV1%predicted (%) 25 (13-39)
RV%predicted (%) 234 (175-327)
TLC%predicted (%) 141 (111-170)
RV/TLC (ratio) 0.7 (0.5-0.8)
DLCO (mmol/minute*kPa) 2.0 (1.4-4.0)
DLCO%predicted (%) 27 (19-40)
6MWD (meter) 287 (111-479)
SGRQ total score (units) 61 (40-82)
Data is presented as median(range). N: number of patients; BMI: Body mass index; FEV1: forced 
expiratory volume in 1 second; RV: Residual volume; TLC: Total lung capacity; DLCO: diffusion 
capacity for carbon dioxide; 6MWD: 6-minute walking distance; SGRQ: St. George’s Respiratory 
Questionnaire.
O2 uptake measurements
We performed O2 uptake measurements in 69 different lobes and of these we 
included 49 in our analysis, see table 2. Measurements were performed in the right 
upper lobe (n=9), right lower lobe (n=7), left upper lobe (n=17) and the left lower 
lobe (n=16). Twenty of 69 measurements (29%) were excluded from analyses because 
of the following reasons: interlobar CV was present (n=8), no full airway seal was 
achieved with the balloon or this seal was lost during measurement (n=5), severe 





Table 2: Gas and quantitative CT measurements
Variables
Number of measurements 49
Oxygen uptake (%O2/second) -0.11 (-0.31- -0.01)
Duration of measurement (seconds) 124 (63-304)
Emphysematous destruction in measured lobe (%voxels <-950HU) 40 (5-60)
Lobar volume (ml) 1574 (912-3009)
Lobar vascular volume (ml) 101 (59-165)
Lobar arterial volume (%) 3.9 (2.5-6.0)
Lobar venous volume (%) 2.6 (1.5-4.0)
Data are presented as median (range). HU: Hounsfield units.
The average O2 uptake was 0.13±0.06% O2 decrease per second, indicating an average 
decrease of 50% Fi02 to 34.4% during a two minute measurement.
A higher degree of lobar emphysematous destruction was significantly associated 
with a lower O2 uptake (Spearman’s rho: 0.39, P<0.01). Furthermore, a lower arterial 
and venous volume on QCT of the measured lobes was significantly correlated with 
lower O2 uptake (respectively rho: -0.46 and -0.47, both P<0.001). Lower arterial 
and venous volume of the lobes were significantly associated with higher lobar 
emphysematous destruction (both rho -0.60, P<0.001). No significant association was 
found between lobar volume and O2 uptake capacity (rho: -0.13, P=0.37). Scatterplots 
can be found in figure 3.
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In this study we investigated a functional endoscopic approach to EBV target lobe 
selection: selective lobar measurement of O2 uptake capacity. A lower O2 uptake was 
significantly correlated with higher lobar emphysematous destruction and lower 
arterial and venous vascular volume of the target lobes.
To our knowledge, this is the first study describing endoscopic lobar O2 uptake 
measurement to improve EBV target selection in patients with severe emphysema. 
Freitag et al. previously demonstrated target zone identification guided by 
endoscopic capnometry and oximetry curves using a similar measurement set-up, 
and were able to improve target zone identification using this technique, but this 
approach did not allow for quantification of lobar uptake capacity (10). Adequate 
target lobe selection for EBV treatment is critical since complete occlusion of a lobe 
with a relatively high uptake capacity for O2 can lead to respiratory insufficiency, 
instead of the patient benefitting from the treatment.
Oxygen uptake in a lobe can be influenced by several factors. First of all, oxygen 
uptake is dependent on the amount of local perfusion. In this study, QCT analysis 
was performed to assess arterial and venous volume in the target lobes, serving as 
a surrogate measure of local perfusion. In future studies, the comparison of Single 
Photon Emission Computed Tomography outcomes to endoscopic lobar O2 uptake 
capacity could be of additional value. Secondly, O2 uptake capacity depends on 
the integrity of local lung tissue and alveoli in the target lobes, which is why we 
related our endoscopic O2 uptake measurements to QCT analysis of emphysematous 
destruction in this study. A third factor that could influence local O2 uptake is variance 
in cardiac output, which in our study was not assessed during the procedure (11). 
A fourth factor is the time between deflation of the Chartis balloon after collateral 
ventilation measurement and the re-inflation of this balloon for oxygen uptake 
measurement. Considering the minimum amount of one minute needed to convert 
to oxygen uptake measurement after CV measurement, our ventilation settings and 
knowing that a median 390ml of air is expired during Chartis measurement in CV 
negative lobes, we do not believe that this factor played a significant role in this 
study (12). A last factor is the alveolar-arterial pressure gradient of oxygen, which 
depends on the FiO2 (11). For standardization reasons we ventilated all our patients 
with an FiO2 of 50%, using the same ventilator settings, avoiding high peak pressures 
of ventilation.
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This study has several limitations. All measurements were performed while 
patients were on positive pressure ventilation during general anesthesia, which 
could have affected measurement outcomes when compared to spontaneously 
breathing patients, however in clinical practice it is recommended to perform both 
the Chartis measurement as well as the EBV procedure under general anesthesia 
(12). In all patients a supranormal standardized FIO2 of 50% was maintained during 
the procedure, in order to magnify the O2 slope signal. The measurements were 
performed during an arbitrary two minutes interval, and to assess O2 uptake, linear 
regression was performed to calculate slope coefficients. Possibly, with extension 
of measurement, the O2 uptake pattern that now exhibited linear relationship 
properties would have exhibited exponential function properties. Our measurement 
set up had a measurement delay of 2 seconds due to catheter length, perhaps in 
future research other measurement techniques such optical fiber probes could be 
used to achieve gas concentration measurements with less delay (13).
Lobes that were diagnosed as CV positive by Chartis measurement were excluded 
from our analysis as the supply of oxygen through interlobar collateral channels 
could disturb oxygen uptake measurements in the isolated lobes. One might even 
elaborate on the possibility of this being an alternative to the current measurement 
of CV using flow instead of gas components.
In our experience, the measurements were feasible, easy to perform and provided 
insight that was of additional value in target lobe selection for EBV treatment. Future 
developments in this field could include the development of a console displaying 
live O2 consumption rate during bronchoscopy.
In conclusion, endoscopic measurement of lobar O2 uptake is feasible in patients 
with emphysema. This new functional endoscopic approach to measure O2 uptake 
capacity at a lobar level can prove an additional diagnostic tool to improve 
identification of a treatment target for lung volume reduction treatment with 
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Background: Absence of interlobar collateral ventilation using the Chartis 
measurement is the key predictor for successfull endobronchial valve treatment 
in severe emphysema. Chartis was originally validated in spontaneous breathing 
patients under conscious sedation (CS), however this can be challenging due to 
cough, mucus secretion, mucosal swelling and bronchoconstriction. Performing 
Chartis under general anesthesia (GA) avoids these problems and may result in an 
easier procedure with a higher succes rate. However, using Chartis under GA with 
positive pressure ventilation has not been validated.
Objectives: In this study we investigated the impact of anesthesia technique, CS 
versus GA, on the feasibility and outcomes of Chartis measurement.
Methods: We retrospectively analyzed all Chartis measurements performed in our 
hospital from October 2010 until December 2017.
Results: We analyzed 250 emphysema patients (median FEV1 26% (range 
12%-52%predicted). In 121 patients (48%) the measurement was performed using 
CS, in 124 (50%) using GA and in 5 (2%) both anesthesia techniques were used. 
In total 746 Chartis readings were analyzed (432 CS, 277 GA and 37 combination). 
Testing under CS took significantly longer than GA (median 19 minutes (range 5-65) 
versus 11(3-35), P<0.001) and required more measurements (3(1-13) versus 2(1-6), 
P<0.001). There was no significant difference in target lobe volume reduction after 
treatment (-1123(-3604-332)ml) in CS versus -1251(-3333--1) in GA, P=0.35.
Conclusions: In conclusion, Chartis measurement under CS took significantly longer 
and required more measurements than under GA, without a difference in treatment 
outcome. We recommend a prospective trial comparing both techniques within the 
same patients to validate this approach.
85
Chartis measurement: conscious sedation versus general anesthesia
INTRODUCTION
Bronchoscopic lung volume reduction using endobronchial one-way valves (EBV) 
has been shown to be clinically effective, and to have an acceptable safety profile 
in selected patients with severe emphysema (1–5). Maximal clinical improvement 
after endobronchial valve treatment is associated with complete lobar atelectasis 
(1,2,6–8). However, lobar atelectasis will not be achieved in the presence of interlobar 
collateral ventilation due to an incomplete interlobar fissure. In approximately 60% 
of the patients with severe emphysema the interlobar fissure is not complete (9). 
Interlobar collateral ventilation can be measured using the Chartis System® (Pulmonx 
Inc., Redwood City, CA, USA).
The Chartis system was originally validated in patients using conscious sedation (8,10). 
However, in clinical practice the Chartis measurement is also often performed using 
general anesthesia for practical reasons. Under conscious sedation, measurements 
are often challenging to perform or even fail, due to increased coughing, mucus 
secretion, bronchoconstriction, swelling of mucosa and difficulty to maintain an 
optimal level of sedation. Therefore, general anesthesia was recently suggested to 
be the preferred and recommended technique for both the Chartis measurement 
and the subsequent endobronchial valve placement due to the ease of airway and 
patient management (11).
To our knowledge, effects of conscious sedation and general anesthesia on the 
Chartis measurement have never been compared in the literature. The objective of 
this study was to investigate the impact of anesthesia technique, conscious sedation 
versus general anesthesia, on both feasibility of the Chartis measurement and the 
outcome of subsequent endobronchial valve placement.
METHODS
Study design and population
Retrospectively, we analyzed data of all patients who underwent a Chartis 
measurement in our University Medical Center Groningen, the Netherlands. From 
October 2010 until December 2017, we performed Chartis measurements in 250 
patients in different trials (“CHARTIS trial” (8), “STELVIO trial” (1), “IMPACT trial” (4), 
“TRANSFORM trial” (5), “BREATH-NL registry” (NCT02815683) and in patients treated 
in a compassionate use setting (Table 1). All trials had prior approval from the local 




Table 1: Patients per anesthesia technique per study
Conscious Sedation General Anesthesia Combination
CHARTIS (2013) [8] 29 (24%) 1 (1%) 0
STELVIO (2015) [1] 80 (66%) 0 (0%) 4 (80%)
IMPACT (2016) [4] 5 (4%) 20 (16%) 1 (20%)
TRANSFORM (2017) [5] 0 (0%) 15 (12%) 0
BREATH-NL 0 (0%) 75 (60%) 0
Compassionate use 7 (6%) 13 (11%) 0
Total 121 (100%) 124 (100%) 5 (100%)
Data is presented as number of cases (percentage of total cases).
Anesthesia technique
Conscious sedation is a drug-induced state of reduced consciousness during which 
patients are able to purposefully respond to verbal commands or light tactile stimuli 
and are able to maintain oxygenation and airway control without intervention 
(12). Conscious sedation was induced with intravenous propofol and remifentanil. 
Medication dosage was titrated up to a level where patients were adequately 
sedated but still arousable and breathing spontaneously. In addition a 1% w/v 
lidocaine spray was applied locally to the upper and lower airways.
General anesthesia is a drug-induced loss of consciousness during which patients 
are not arousable, even by painful stimulation, spontaneous ventilation cannot be 
maintained and an artificial maintenance of open airway is necessary (12). General 
anesthesia was induced through administration of intravenous propofol and 
remifentanil and muscle relaxation was achieved with rocuronium bromide. Patients 
were intubated with a flexible 9 mm endotracheal tube and positive pressure 
ventilation was applied with target settings of low ventilation frequency (8-10x/
minute), long expiratory settings (inspiratory/expiratory ratio of 1:3) and positive 
end-expiratory pressure of 3cm H20 (11).
Chartis measurement
Collateral ventilation measurements were performed using the Chartis System® 
(Pulmonx Inc., Redwood City, CA, USA). The Chartis system consists of a catheter, 
with an inflatable balloon at the tip, which can be advanced through the 2.8 mm 
or larger working channel of a bronchoscope (figure 1). Inflation of the balloon 
allows for temporary occlusion of the airway, during which airflow coming from the 
occluded lobe can be assessed (13). Expired airflow volume, pressure and resistance 
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measurements are analyzed and visualized by the Chartis console. Distinctive airflow 
patterns allow for assessment of collateral ventilation status (figure 2) (9).
 
Figure 1: Chartis system® (Pulmonx Inc., Redwood City, CA, USA). Console with catheter (Panel A). Catheter 
with inflated balloon at tip (Panel B). Bronchoscopic view of inflated balloon at catheter tip in airway (Panel C). 
Bronchoscopic view through inflated balloon at catheter tip in airway (Panel D).
Figure 2: Chartis measurement reports for the 4 different categories: Negative collateral ventilation under 
conscious sedation (Panel A), negative collateral ventilation under general anesthesia (Panel B), positive collat-






We analyzed the Chartis measurements that were performed in the pre-determined 
treatment target- and ipsilateral lobes.
Our primary outcome was the total duration of Chartis measurement, defined as 
the total duration of all measurement attempts combined. Secondary outcomes 
were the number of Chartis measurements performed per patient, number of 
measurements per lobe, amount of lobes measured, expired airflow volume 
measured with Chartis, target lobe volume reduction (TLVR) after treatment, and 
Chartis outcome category. The Chartis outcome was categorized by the treating 
physician in 4 different categories: 1) negative collateral ventilation 2) positive 
collateral ventilation 3) undetermined measurement (signal output but not possible 
to determine collateral ventilation status, caused by for example touching of the 
bronchial wall by the Chartis catheter tip, secretion occlusion of the catheter leading 
to low/no flow or measurement distortion by coughing and patient exhaling during 
exertion) and 4) discarded measurement (not possible to obtain valid signal output 
due to loss of balloon seal and total catheter blockage due to excessive mucus).
TLVR was calculated using different quantitative high resolution computed 
tomography software per study protocol. Scans were analyzed using Thirona LungQ 
(Nijmegen, The Netherlands) (STELVIO, BREATH-NL registry and compassionate use), 
VIDA Diagnostics software (Coralville, IA, USA) (TRANSFORM and IMPACT) or MedQia 
software (Los Angeles, CA, USA) (CHARTIS).
Statistical analysis
To compare differences in patient characteristics, measurements duration, number 
of Chartis measurements, number of measurements per lobe, amount of lobes 
measured, expired airflow volume and TLVR between conscious sedation and 
general anesthesia, an Independent-Samples T-test was performed in case of normal 
distribution of data and a Mann-Whitney-U test in case of non-normal distribution. 
P-values below 0.05 were considered statistically significant. All statistical analyses 
were performed using SPSS version 22 (IBM, New York, NY, USA).
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RESULTS
Of the 250 included patients, 121 (48%) patients underwent conscious sedation 
and 124 (50%) patients underwent general anesthesia. Five patients (2%) received 
both anesthesia techniques after conversion from conscious sedation to general 
anesthesia; these were not used in the analyses (see figure 3 for patient flowchart, 
patient characteristics are shown in table 2). No direct anesthesia related 
complications were observed in either groups.
 
Figure 3: Patient flowchart. Patients who received both conscious sedation and general anesthesia were not 
included in the analysis. CV-: negative collateral ventilation; CV+: positive collateral ventilation.
 
The Chartis measurement outcomes per anesthesia technique are provided in table 
3. Chartis measurement under conscious sedation took significantly (P<0.001) longer 
than under general anesthesia (median 19 minutes (range 5-65) versus 11 (3-35)), 
required a significantly (P<0.001) higher number of measurements (3 (1-13) versus 2 
(1-6) and required a significantly (P<0.001) higher number of measurements per lobe 
(2(1-7) versus 1 (1-3). The proportions of undetermined and discarded measurements 
and the amount of lobes measured per patient were not significantly different 




Table 2: Patient characteristics
Characteristics Conscious Sedation General Anesthesia Combination
n 121 124 5
Female/Male (%) 60/40 68/32 80/20
Age (years) 60 (36-78) 62 (42-78) 54 (47-68)
BMI (kg/m2) 23.8 (17-37) 23.2 (16-35) 22.6 (20-26)
Pack-years (years)* 35 (0-110) 39 (8-148) 35 (18-60)
FEV1%predicted (%)* 27.0 (12-52) 25.8 (12-48) 26.0 (23-32)
RV%predicted (%)* 216.0 (120-361) 232.5 (130-484) 245.0 (182-263)
6MWD (meter)* 361.3±95.4 316.6±100.3 411.8±72.7
SGRQ total score (units) 60.3±12.8 60.0±11.3 56.1±8.1
Target lobe volume (ml) 1747 (780-4666) 1632 (956-3755) 2146 (1067-2746)
Data is presented as mean ± standard deviation in case of normal distribution of data and as 
median(range) in case of non-normal distribution. BMI: Body mass index; FEV1: forced expiratory 
volume in 1 second; RV: Residual Volume; 6MWD: 6-minute walking distance; SGRQ: St. George’s 
Respiratory Questionnaire. Difference between conscious sedation and general anesthesia was 
analyzed with an Independent-Samples T-test in case of normal distribution of data and a Mann-
Whitney-U test in case of non-normal distribution. *P<0.05 between conscious sedation and 
general anesthesia.
Median TLVR in the conscious sedation group was -1123(-3604-332)ml (relative TLVR 
72%) compared to -1251(-3333--1)ml (relative TLVR 77%) in the general anesthesia 
group. Differences in both absolute as well as relative TLVR were not significant 
between anesthesia techniques.
In total 746 Chartis measurements (432 conscious sedation, 277 general anesthesia 
and 37 combination) were performed in the pre-determined target- or ipsilateral 
lobes, of which 373 were categorized as negative collateral ventilation, 151 positive 
collateral ventilation, 125 were undetermined and 97 were discarded measurements. 
Under conscious sedation the Chartis catheter balloon ruptured 3 times compared 
to once under general anesthesia.
In patients with absence of collateral ventilation, the expired airflow volume 
was significantly (P=0.015) higher under conscious sedation than under general 
anaesthesia (490ml (range: 6-2504) versus 390ml (range: 34-1561).
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To our knowledge, this is the first study comparing conscious sedation and general 
anesthesia during bronchoscopic evaluation of interlobar collateral ventilation with 
Chartis in patients with severe emphysema. The Chartis testing under conscious 
sedation took significantly longer and required a higher number of measurements 
in total and per lobe than general anesthesia, indicating the ease of use of Chartis 
under general anesthesia. In the EBV treated patients, after a CV negative Chartis 
measurement, no significant differences in TLVR were found between the conscious 
sedation and general anesthesia group, suggesting no inferiority of the diagnostic 
value of Chartis under general anesthesia.
The observed differences in duration and number of measurements could be 
the result of more frequent presence of mucus, coughing, bronchus constriction, 
airway wall edema and sedation problems, causing catheter obstruction in the 
conscious sedation group leading to more complex procedures and more difficult 
interpretation of Chartis results.
There are no studies reported that compared various techniques of anesthesia 
with respect to feasibility. A study by Gesierich et al., compared airway collapse 
during Chartis measurement under spontaneous breathing and jet ventilation and 
recommended to use spontaneous breathing to prevent airway collapse (14).
In the patients who received general anesthesia in our study positive pressure 
ventilation via an endotracheal tube was applied.
Recently, a best practice recommendations panel on endoscopic lung volume 
reduction favored the use of general anesthesia for Chartis measurement and the 
subsequent endobronchial valve placement due to the ease of use, airway and 
patient management (11).
Five patients received both conscious sedation as well as general anesthesia. These 
patients were converted from conscious sedation to general anesthesia because 
the treating physician was unable to perform a valid measurement under conscious 
sedation, due to mucus presence, patient unrest, coughing and low flow. The fact 
that in some patients measurement was only possible in a general anesthesia setting 
might already indicate the better feasibility of this approach.
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Arguments against the use of general anesthesia for Chartis measurement could 
be the higher dosage of medication received, compared to conscious sedation, 
as well as the intubation and ventilation of severe emphysema patients. Higher 
cost of the application of general anesthesia should be considered, especially in 
limited resource settings. On the other hand, the EBV procedure is much easier and 
faster to perform under general anesthesia. Furthermore, in our hospital patients 
are always scheduled for a combined Chartis measurement with a subsequent 
EBV procedure (and never for a diagnostic Chartis procedure alone to avoid an 
unnecessary additional bronchoscopy), making the use of general anesthesia for 
the Chartis procedure more practical. In addition, no anesthesia-related adverse 
events were reported in our patients. The use of both conscious sedation as well as 
general anesthesia is deemed safe in interventional pulmonology (15).
No significant differences in TLVR after treatment between the conscious sedation 
and general anesthesia group were found. This is an important finding since the 
Chartis measurement was not yet validated under general anesthesia. The absence 
of collateral ventilation in combination with successful EBV placement, resulting in 
sufficient target lobe volume reduction, is the driver for treatment success as TLVR 
is a predictor for clinically meaningful change after treatment (16,17).
A higher percentage of positive collateral ventilation measurements was found in 
the conscious sedation technique. One explanation could be the improved patient 
selection over time by quantitative high resolution computed tomography (fissure) 
analysis, which decreased the number of patients with positive collateral ventilation 
outcomes in Chartis measurement in the trials. In addition, the objective of the 
CHARTIS study, in which almost all patients underwent conscious sedation, was 
to determine whether Chartis assessment of collateral ventilation could predict 
significant TLVR after EBV placement, actively including patients with both negative 
as well as positive collateral ventilation status (8).
Baseline characteristics were significantly different for FEV1, RV and 6MWD, with the 
more severe patients being in the general anesthesia group. This difference can be 
explained by the fact that general anesthesia was more frequently applied in later 
trials which were open to inclusion of patients with more severe disease. We do not 
believe that the severity of emphysema influenced Chartis measurement outcomes, 
especially because (non-)intact fissures are probably not caused by emphysematous 




The expired total airflow volume in patients with negative collateral ventilation was 
significantly higher under conscious sedation than under general anesthesia. This is 
an interesting finding, since we assumed that patients under conscious sedation with 
spontaneous breathing would rely on the elasticity of the lobe to exhale through 
the catheter, while patients under general anesthesia would have both elasticity as 
well as driving force from positive pressure in the adjacent lobe(s). Another possible 
explanation could be that due to an easier procedure under general anesthesia the 
sampling time was shorter leading to a lower amount of analysed airflow volume. 
The observed difference did not lead to a difference in diagnostic outcome.
A limitation of our trial is that most Chartis measurements under conscious sedation 
were carried out in the earlier studies, while at that point Chartis measurement 
performance experience was limited, possibly leading to a learning curve bias. A 
study by Herzog et al. for example described a 12% reduction of inconclusive Chartis 
measurements, due to increasing experience of the bronchoscopists, in a 5 year 
period (18). Another limitation of our study is that patients were retrospectively 
included from several trials, introducing a possible selection bias. On the other 
hand, we sequentially included all patients who underwent Chartis measurement 
in our center during the given timeframe and did not leave patients out of the 
analysis. In addition, we were able to include a large number of measurements 
compared to other retrospective studies investigating Chartis (14,18). Furthermore, 
all measurements were performed in one specialised treatment center with only two 
physicians performing the measurements, leading to a high level of standardisation.
In conclusion, in this retrospective study we observed significantly longer duration 
of the Chartis measurement as well as a higher number of attempts needed under 
conscious sedation compared to general anesthesia. This could indicate that the 
feasibility of the Chartis measurement is better under general anesthesia. The 
results of this study suggest advantages of performing Chartis measurement under 
general anesthesia, without losing diagnostic power. We recommend to perform a 
prospective trial comparing both techniques within the same patients to validate 
this approach.
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Background: Absence of interlobar collateral ventilation is key to successful 
endobronchial valve treatment in patients with severe emphysema and can be 
functionally assessed using the Chartis® measurement. Chartis has been validated 
during spontaneous breathing, undergoing procedural sedation (PS), but can also 
be performed under general anesthesia (GA). Performing Chartis under PS is often 
challenging because of coughing, mucus secretion and difficulties in maintaining 
an adequate level of sedation. The study objective was to investigate whether there 
is a difference in Chartis measurement outcomes between PS and GA.
Methods: In this prospective study patients underwent Chartis measurements 
under both PS and GA. Study outcomes were Chartis measurement duration, number 
of measurements, feasibility and success rate.
Results: We included 30 patients with severe emphysema (mean age 62 years and 
median FEV1 29% of pred.). Chartis measurement duration was significantly longer 
under PS than under GA (mean 20.3±4.2 minutes versus 15.1±4.4, P<0.001). There 
was no difference in the number of measurements performed (median 2 (range 1-3) 
for PS versus 1 (1-3) for GA, P=1.00). Chartis measurement was more feasible during 
GA (median sum of all feasibility scores: 12 (range 6-26) for PS versus 7 (5-13) for GA, 
P<0.001), with no statistical difference in success rate: 77% of cases for PS versus 
97% under GA, P=0.07.
Conclusion: This study shows that Chartis measurement under general anesthesia 
is faster and more feasible to perform compared to procedural sedation, without 
affecting measurement outcomes.
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INTRODUCTION
Bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV) 
is an effective and safe treatment for selected patients with severe emphysema 
(1–4). To achieve EBV treatment benefit, interlobar collateral ventilation (CV) must 
be absent, as the presence of CV prevents the desired atelectasis of the target lobe 
(5). The presence of CV can be assessed using indirect measurement techniques 
such as quantitative computed tomography fissure analysis and hyperpolarized 
gas magnetic resonance imaging or direct techniques such as collateral flow 
measurement during bronchoscopic assessment with the Chartis System® (Pulmonx 
Inc., Redwood City, CA, USA)(6,7). The Chartis system consists of a catheter which is 
designed to be advanced through the working channel of a flexible bronchoscope 
and uses an inflatable balloon at the tip of the catheter to selectively occlude the 
entrance of a lung lobe (see figure 1). The system measures flow from the occluded 
lobe and calculates the resistance to airflow through collateral channels and 
quantifies the amount of CV within a specific lobe (8).
 




In our BLVR treatment expert center, all patients scheduled for EBV treatment 
undergo a Chartis measurement to determine CV status. Chartis measurement was 
originally validated in patients breathing spontaneously undergoing procedural 
sedation (PS) (9). However, performing a Chartis measurement under PS can be 
very challenging because of problems with catheter placement caused by coughing 
reflexes of the patient, mucus secretions that can occlude the catheter, swelling of 
the airway mucosa causing challenging measurements and difficulties in maintaining 
a sufficient level of sedation. Although in several recent EBV trials as well as in our 
ongoing regular treatment program BREATH-NL (NCT02815683) we have performed 
Chartis measurement under general anesthesia (GA), the measurement has not yet 
been validated under GA (2–4). We recently published a retrospective analysis on 
this topic, suggesting advantages of Chartis measurement under GA with shorter 
procedure times and fewer measurements necessary, without a difference in target 
lobe volume reduction after EBV treatment (10). The objective of this study was to 
prospectively compare Chartis measurement under PS versus GA. We hypothesized 
that Chartis measurement under GA would result in faster procedures with higher 
physician assessed feasibility and with similar diagnostic outcome.
METHODS
Study design and participants
We performed a single center prospective study in which we included patients with 
severe emphysema (NCT03205826), who met the inclusion criteria for EBV treatment 
(5). For safety reasons, patients that met the following criteria were excluded from 
participation: forced expiratory volume in one second (FEV1)<20% of predicted, 
residual volume/total lung capacity (RV/TLC) ratio >70%, pCO2>6.5 kPa at baseline at 
room air, right ventricular systolic pressure >40mmHg on echocardiogram, 6 minute 
walking distance <200 meter, known intolerance to lidocaine or any medical reason 
that warranted a short procedure.
The study was approved by the University Medical Center Groningen medical ethics 
committee (NL62374.042.17) and all patients provided written informed consent.
Procedure
CV status was evaluated in all patients using Chartis measurement under PS, followed 
by Chartis measurement under GA in the same procedure. The same lobes were 
assessed under PS and under GA. In all patients the measurements were performed 
in the target lobe for EBV treatment and when indicated the measurements were 
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also performed in the ipsilateral or secondary target lobes. Chartis measurement 
was terminated when either absence of collateral ventilation was confirmed by an 
airway flow gradually approaching zero (with airway resistance >10cm H2O x ml/s 
for PS) in combination with immediate return of airway flow upon release of the 
balloon catheter (ruling out catheter obstruction), or when the presence of collateral 
ventilation was confirmed with the observation of a continuous, non-decreasing, 
expiratory airway flow during >6 minutes or totaling >1 liter (11,12). All Chartis 
measurements were performed by one interventional pulmonologist, who had 
previous experience with this measurement under PS and GA (DJS).
Anesthetic management
Anesthetic management consisted of two phases: PS and GA. Patient monitoring 
during both phases consisted of 3-lead ECG, SpO2, non-invasive blood pressure 
monitoring, end-tidal CO2 measurement and electroencephalography based depth 
of sedation monitoring using a BIS monitor (BIS VISTA®, Medtronic, Dublin, Ireland).
PS was induced using infusions of propofol and remifentanil. Propofol (20mg/ml) 
was administered by effect-site (Ce) targeted-controlled infusion (TCI) using the 
Schnider model with a starting target Ce concentration of 1 µg/ml (13). Remifentanil 
(50 µg/ml) was administered by effect-site (Ce) TCI using the Minto model starting 
at an initial target Ce of 1.0 ng/ml (14). Sedation depth was controlled primarily by 
adjusting the propofol target Ce concentration while the target remifentanil Ce was 
reduced on indication but rarely increased above 1.0 ng/ml. Lidocaine 10mg/ml was 
applied topically to the larynx by the interventional pulmonologist. Sedation was 
maintained in the time period between the PS phase and the GA phase.
In order to pre-oxygenate the lungs adequately for the induction of GA, patients 
were administered 100% O2 through a tight fitting face mask while still under PS. 
After pre-oxygenation Ce-propofol and Ce-remifentanil were increased to induce GA, 
rocuronium-bromide 0.3-0.6 mg/kg was administered and endotracheal intubation 
was performed by the attending anesthesiologist using a cuffed Shiley™ Hi-contour 
Oral/Nasal Tracheal Tube (Covidien™, Mansfield, USA) with an internal diameter of 
9mm. Thereafter GA was maintained with TCI-propofol and remifentanil and the 
patients lungs were mechanically ventilated. The primary ventilator settings were: 
volume controlled ventilation mode, fraction of inspired oxygen 50%, positive end-
expiratory pressure 3cm H20, tidal volumes of 4 to 6ml/kg, respiratory rate 10/min 
and an inspiratory:expiratory ratio of 1:3 to 1:4. The adjustment of these settings, to 





The primary outcome measure was the difference in duration of Chartis measurement 
between the sedation and GA. Secondary outcome measures were the time until 
the patient was sufficiently sedated to undergo Chartis measurement, success rate 
of Chartis measurement, number of measurements performed and qualitative 
feasibility assessment between the two anesthesia methods. The duration of the 
Chartis measurement was defined as the time between the start of the applicable 
anesthesia phase (PS or GA) and the withdrawal of the Chartis catheter from the 
bronchoscope after Chartis measurement. Start of PS phase was defined as the 
start of propofol or remifentanil. Start of the GA phase was defined as the increase 
of propofol and remifentanil dosage for induction of GA. The time until the patient 
was sufficiently sedated to undergo Chartis was defined as the time between start of 
the PS or GA phases and the first advancement of the Chartis catheter through the 
bronchoscope. Measurements were considered successful when collateral ventilation 
status was classified as either positive or negative. A single measurement was defined 
as the data collected between initiation and termination of the measurement on the 
Chartis console. Chartis measurement was only performed once per lobe per patient, 
unless a measurement was considered unsuccessful. Feasibility of the measurement 
was scored for both PS as well as GA by the physician performing the measurement, 
using a 1-10 visual analog scale, with lower scores indicating better feasibility. Five 
sub-scores were scored: presence of mucus, amount of coughing, degree of airway 
collapse, need for breathing instruction (for PS only) and measurement feasibility. 
We calculated the sum of all sub-scores to assess overall feasibility.
Statistical analysis
The sample size calculation was based on a previous study from our group, in 
which the average time of Chartis measurement was 1283±720 seconds under PS 
and 818±477 seconds under GA (10). A paired samples t-test was performed and to 
reach a power of 80% with an alpha level of 0.05 and considering a 10% drop-out 
rate, a total of 30 patients were required.
Differences in duration, time until the patient was sufficiently sedated to undergo 
Chartis, number of measurements and feasibility score outcomes of the Chartis 
measurement between PS and GA were analysed using a paired samples t-test 
in case of normal distribution or a Wilcoxon signed rank test in case of non-
normal distribution of data. The difference in success rate between the anesthesia 
methods was analysed using McNemar’s test. Confidence intervals for non-normally 
distributed data were determined using Hodges Lehmann Estimator. Statistical 
103
Chartis measurement: procedural sedation versus general anesthesia
analyses were performed using SPSS (IBM, New York, NY, USA). P-values<0.05 were 
considered statistically significant.
RESULTS
In total, 31 patients signed informed consent, of which in 30 patients Chartis 
measurements were performed between April 2018 and January 2019. One patient 
was excluded from further analysis because severe bronchitis was observed during 
bronchoscopy, leading to ineligibility for EBV treatment and therefore no Chartis 
measurement was performed. The remaining thirty patients were included in the 
final analysis (23% male, mean age 63±6 years and median FEV1 29% (range 21-56) of 
predicted). Baseline characteristics can be found in table 1. All patients completed 
the study without unexpected anesthesia related complications or unexpected 
procedure related complications.






Pack-years (years) 49 (15-126)
FEV1%predicted (%) 29 (21-56)
RV%predicted (%) 227 (181-300)
RV/TLC (ratio) 0.6 (0.6-0.8)
pC02 in arterial blood gas (kPa) 5.3±0.6
6MWD (meter) 369 (120-477)
SGRQ total score (units) 54.7±11.0
Data are presented as mean ± standard deviation in case of normal distribution of data and as 
median(range) in case of non-normal distribution. BMI: Body mass index; FEV1: forced expiratory 
volume in one second; RV: Residual volume; TLC: Total lung capacity; 6MWD: 6-minute walking 





A total of 48 Chartis measurements were performed under PS of which 19 
were classified as CV negative and 10 were classified as CV positive. During 7 
measurements we encountered a no flow state and 12 measurements were classified 
as unknown CV status. Forty-eight measurements were performed under GA of 
which 23 were classified as CV negative and 13 were classified as CV positive. 
During 10 measurements we encountered a no flow state and 2 measurements 
were classified as unknown CV status.
Chartis measurement took significantly longer under PS than under GA. In addition, 
with the patient under PS, it took significantly longer before the patient was 
sufficiently sedated to undergo Chartis compared to GA. No significant difference 
in the number of measurements performed was observed. The success rate of 
Chartis measurement was higher under GA compared to PS, however not statistically 
significant. Chartis outcomes are provided in table 2.
Discrepancies in CV status outcome between PS and GA were encountered in 4 
measurements. Two measurements that were classified as CV positive under PS 
were, when measured in the same lobe of the same patient, classified as CV negative 
during GA, while two other measurements were classified CV negative under PS and 
CV positive under GA. Out of these 4 patients, 3 underwent EBV treatment and 1 
patient was not treated based on a significant contribution of the occluded target 
lobe to the overall gas exchange of the patient. In one patient who was classified 
as CV positive under PS and as CV negative under GA, full lobar atelectasis was 
observed on high resolution computed tomography scan (HRCT) 6 weeks after EBV 
treatment. In two patients, who were classified as CV negative under PS and as CV 
positive under GA, treatment did not result in lobar atelectasis on HRCT at 6 weeks 
follow-up.
Chartis measurements were more feasible under GA compared to PS. During PS, 
mucus score, coughing score and measurement feasibility were significantly worse 
compared to GA, while airway collapse did not differ between both methods (table 
2).
There was no difference in median Ce propofol during the start of Chartis 
measurement under PS versus GA. The median Ce remifentanil during the start of 
Chartis measurement was significantly lower during PS than during GA. The median 
BIS score at the time of start Chartis measurement was significantly higher during PS 
compared to GA. All patients were mechanically ventilated during the GA phase. The 
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median tidal volume was 5ml/kg (3-7) and the median plateau pressure observed 
was 18 cm H20 (13-38). During PS, a mean of 294±55mg lidocaine was administered 
topically to the patients.







Duration of total Chartis procedure per patient 
(minutes)
20.3±4.2 15.1±4.4 5.2 [3.4-7.1] P<0.001
Time until patient was sufficiently sedated to 
undergo Chartis measurement (minutes)
12.5±3.0 7.6±1.8 4.9 [3.7-6.1] P<0.001
Number of measurements per patient (number) 2 (1-3) 1 (1-3) 0 [0-0] P=1.00
Success rate (%) 77% 97% NA P=0.07
Feasibility
Sum of feasibility scores (score) 12 (6-26) 7 (5-13) 6 [4-8] P<0.001
Mucus (score) 4 (2-8) 3 (1-5) 2 [1-3] P<0.001
Coughing (score) 4 (1-8) 1 (1-1) 3 [2-4] P<0.001
Airway collapse (score) 2 (1-8) 1 (1-4) 1 [0-1] P=0.06
Feasibility (score) 3 (1-7) 2 (1-4) 1 [1-2] P<0.01
Breathing instruction during procedural sedation 
(score)
2 (1-10) NA NA NA
Anesthesia
Propofol effect site concentration at time of start 
Chartis measurement (µg/ml)
3 (1-5) 3 (2-5) -0.4 [-1-0.1] P=0.09
Remifentanil effect site concentration at time of 
start Chartis measurement (ng/ml)
1 (1-2) 4 (2-5) -3 [-3--3] P<0.001
BIS score at time of start Chartis measurement 
(score)
76 (46-88) 39 (24-64) 35 [29-38] P<0.001
Data are presented as mean ± standard deviation in case of normal distribution of data and 
as median (range) in case of non-normal distribution. The differences between the anesthesia 
methods are presented as mean or median [95% confidence interval]. Confidence intervals for 
non-normally distributed data were determined using Hodges Lehmann Estimator. Differences 
in outcomes between procedural sedation and general anesthesia were analyzed with a paired 
samples t-test in case of normal distribution of data or a Wilcoxon signed rank test in case 
of non-normal distribution of data. The difference in success rate of the measurements was 
analysed using a McNemar’s test. NA: Not applicable. BIS: Bispectral index. Mucus, coughing, 
airway collapse, feasibility and breathing instruction were scored on a 0 to 10 scale, with a score 
of 0 indicating, no mucus, no coughing, no airway collapse, very feasible measurement and no 
breathing instruction, and a score of 10 indicating, large amounts of mucus, severe coughing, 






This first prospective study comparing Chartis measurement of CV under PS versus 
GA showed that Chartis measurement took significantly longer and was less 
feasible under PS compared to this measurement under GA. The performance of 
Chartis measurement was less feasible under PS, with more mucus and coughing 
problems. No statistical differences were found in the number of measurements or 
the measurement success rate.
Chartis measurement is an important tool used to assess interlobar CV status and 
achieve EBV treatment success, and should ideally be performed in circumstances 
that allow for fast and effective measurement, preferably in the same session in 
which the EBV placement is performed (5). The differences in duration and feasibility 
between PS and GA that we found are likely to be caused by more mucus production, 
causing catheter obstruction, or coughing resulting in problems with catheter 
positioning, as well as maintaining adequate sedation levels in the PS group, all 
causing more difficult measurement and interpretation of Chartis results.
The results of this study are in line with a retrospective analysis performed by our 
group in which longer and more frequent measurements under PS were observed, 
without a difference in target lobe volume reduction after EBV treatment (10). The 
nominal success rate of Chartis measurement in this study was higher for GA, but this 
difference was not statistically significant. In addition, and supportive of our findings, 
a recently published retrospective analysis by Thiruvenkatarajan et al. comparing 
PS and GA suggests better interventional conditions, patient comfort and reduced 
anesthetic time under GA (15).
No direct unexpected anesthesia related complications or direct unexpected 
procedure related complications were observed in our study. Thiruvenkatarajan et 
al. describe occurrence of mild hypotension periods during EBV treatment under GA, 
in line with expected blood pressure decline after induction of GA and responding 
to vasopressor bolusses. One case of severe hypotension in the same study was 
observed which was ascribed to possible anaphylaxis and led to procedure 
termination (15). Post-treatment expected complications were not registered for 
our study. In the recently published LIBERATE trial, post EBV treatment complications 
were compared between procedures performed under PS versus GA: chest pain 
occurred in 40% of patients under PS versus 18% under GA, pneumothorax occurred 
in 24% of patients under PS versus 33% under GA and COPD exacerbations were 
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observed in 22% of patients after PS versus 18% under GA, however no statistical 
testing was performed to compare the complication rates between the anesthesia 
methods. In the same trial, no difference in FEV1 outcome after EBV treatment 
between the two anesthesia methods was found (4).
Next to the above mentioned disadvantages, performing Chartis under PS also has 
potential advantages over GA: lower dosages of medication are necessary and no 
intubation and mechanical ventilation is required. Even though the performance of 
Chartis measurement under GA is more resource intensive, invasive for the patient 
and sometimes unavailable in BLVR centers, the use of GA for Chartis measurement 
is advocated by an expert panel on BLVR (5).
A theoretical argument against the performance of Chartis under GA is that the 
use of positive pressure ventilation might open CV channels, which would not be 
open under spontaneous breathing circumstances, leading to a false positive CV 
outcome. In the current study we did not observe any relevant differences in CV 
status outcomes between PS and GA. This observation is further supported by our 
previously published retrospective analysis in which no difference in target lobe 
volume reduction outcome between the two methods was seen after EBV treatment 
(10).
Because patients in this study received PS before conversion to GA, the time needed 
to induce GA could have hypothetically been reduced and led to underestimation of 
the time before the patient was sufficiently sedated to undergo Chartis measurement. 
With the TCI-technique used in our institution, however, the time needed to increase 
remifentanil from PS to GA levels using target-controlled infusion is approximately 
80 seconds while the time needed to achieve GA levels of remifentanil when starting 
from 0 is approximately 90 seconds. In other words, the sedation Ce’s of propofol 
and remifentanil have not led to a significant reduction of the time needed to 
induce GA while in addition during the induction of GA, the anesthesiologist had 
to wait around 3 to 4 minutes for the neuromuscular blockade needed for tracheal 
intubation to take effect. Finally, all feasibility outcomes were scored by only one 
physician, which might lead to an observation bias. Furthermore, we only assessed 
physician feasibility, while ideally the experience of the patients should be taken in 
consideration as well. Unfortunately this is challenging to investigate as procedure 




A strength of our study is that all Chartis measurements were performed by one 
interventional pulmonologist with experience with Chartis under both anesthesia 
techniques in one specialized treatment center, which increased standardization. In 
addition, all patients received both anesthesia techniques in a standardized fashion 
with medication dosage models and fixed ventilator settings. In our opinion, the fact 
that all patients received both PS as well as GA is a strength of our study. Ideally, the 
order in which patients undergo PS or GA first should be randomized, however we 
considered this approach unfeasible because of practical limitations.
In conclusion, we suggest performing Chartis measurement under general 
anesthesia because of higher feasibility and shorter procedure times compared 
to procedural sedation, without losing diagnostic power. The results from this 
study might result in more efficient and feasible Chartis measurement in future 
endobronchial valve treatment.
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Temporary right middle lobe occlusion with a 
blocking device to enable collateral ventilation 












Background: Absence of interlobar collateral ventilation is essential to achieve lobar 
volume reduction after endobronchial valve treatment (EBV) and can be assessed 
using the Chartis measurement. However, especially in lower lobe measurements, 
Chartis can be complicated by the ‘no flow phenomenon’, during which a sudden 
cessation of flow is observed, leading to an unreliable measurement. If this 
phenomenon occurs in the right lower lobe, when measuring collateral flow over 
the right major fissure, the entrance to the right middle lobe should be occluded 
and the Chartis balloon should be placed in the right upper lobe. Both Watanabe 
spigots and balloon catheters can be used to achieve occlusion.
Methods: We performed a retrospective analysis of patients scheduled for EBV 
treatment in an EBV registry between 09/2016 and 09/2019.
Results: We included 15 patients with severe emphysema (median age 63 (range 
47-73) years, 73% female and FEV1 24% (19-36) of predicted), who required temporary 
middle lobe occlusion (12 Watanabe spigot/3 balloon catheter). After occlusion, a 
reliable Chartis outcome was obtained in all patients.
Conclusion: Temporary middle lobe occlusion using a blocking device is helpful 
in obtaining a reliable Chartis outcome in case of a right lower lobe no flow 
phenomenon.
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INTRODUCTION
The absence of interlobar collateral ventilation is essential to achieve lobar volume 
reduction with endobronchial valve (EBV) treatment in patients with severe 
emphysema and can be assessed using the Chartis® (Pulmonx, USA) measurement 
(1–4). Chartis measurement can be complicated by the ‘no flow phenomenon’, in 
which dynamic expiratory airway collapse is believed to cause a sudden cessation 
of flow during measurement, leading to an unreliable Chartis measurement (5). 
Literature shows that this can occur in up to a third of all measurements and most 
frequently affects the lower lobes (5–7). Normally, Chartis measurement is performed 
in the lobe selected for treatment with EBV. When the no flow phenomenon occurs 
during measurement in the left lung, measurement in the adjacent lobe can easily 
be performed to assess the integrity of the left major fissure (8). However, in case 
of no flow in the right lower lobe, measurement of the right upper lobe may not 
be reliable because collateral flow originating from the right middle lobe, due to 
common incompleteness of the right minor fissure, can result in false positive Chartis 
outcomes (1). If the middle lobe is not occluded, the measurement in the right upper 
lobe only measures the collateral flow over the right upper lobe fissure (part of the 
major fissure and minor fissure) and not the right major fissure.
METHODS
We performed a retrospective analysis, in which we included all patients with the 
right lower lobe as primary EBV target and in which the no flow phenomenon 
occurred during Chartis measurement in the right lower lobe.
All patients were scheduled for treatment in the Dutch national EBV treatment 
registry (BREATH-NL) between 09/2016 and 09/2019 (Clinicaltrials.gov identifier: 
NCT02815683). Chartis measurements were performed in all patients regardless of 
fissure integrity scores. The presence of collateral ventilation was confirmed when a 
continuous, non-decreasing, expiratory airway flow was observed during >6 minutes 
or earlier with a similar pattern when totaling >1 liter (8). Every patient underwent 
Chartis measurement under general anesthesia using a previously described 
approach (9). Target lobe volume and fissure integrity were assessed using the StratX 
quantitative CT Platform (Pulmonx, USA). According to the Ethics committee of our 
hospital this study did not fall within the scope of the WMO (Dutch Medical Research 
with Human Subjects Law) and therefore formal ethical approval was not needed. 




To achieve the desired temporary occlusion of the right middle lobe, both Watanabe 
spigots® (Novatech, France) and Extractor® Pro retrieval balloon catheters (Boston 
Scientific, United States), were used. The Watanabe spigot (figure 1) is a silicon 
bronchial filler, which is frequently used for persistent pneumothorax, hemoptysis 
and bronchopleural fistula, and is available in three sizes: 5, 6 and 7mm diameter 
(10). The retrieval balloon (figure 2) can be inflated to any desired diameter between 
5 and 20mm and can be replaced by any local available alternative balloon.
Our primary outcome was the success rate of right upper lobe Chartis measurement 
of the right major fissure after occlusion of the right middle lobe and placement of 
the Chartis balloon in the right upper lobe. Our secondary outcome was the amount 
of target lobe volume reduction after EBV treatment.
 
Figure 1: Panel A: Watanabe spigot. Panel B: Watanabe spigot held by biopsy forceps, which can 
be used for both placement and removal of the spigot.
Case report
A 63 year old female with severe emphysema (forced expiratory volume in 1 second 
(FEV1) 25% of predicted and residual volume (RV) 214% of predicted) was scheduled 
for EBV treatment in our hospital. The pre-determined target for treatment was the 
right lower lobe (51% of voxels <-950 Hounsfield Units). We were initially unable to 
obtain a reliable Chartis measurement in the right lower lobe, as we encountered 
the no flow phenomenon (figure 3A). After the occlusion of the right middle lobe 
with a Watanabe spigot, we performed a Chartis measurement in the right upper 
lobe which indicated absence of interlobar collateral ventilation of the right major 
fissure (figure 3B). Subsequently, five endobronchial valves were placed in the right 
lower lobe. Six weeks after treatment, the patient achieved a target lobe volume 
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reduction of 1201ml, had an FEV1 of 40% of predicted (69% relative increase) and an 
RV of 148% of predicted (31% relative reduction).
 
Figure 2: Panel A: Watanabe spigot occluding the entrance of the right middle lobe. Panel B: 
Balloon catheter occluding the entrance of the right middle lobe.
 
Figure 3: Panel A: Chartis measurement output indicating no flow phenomenon in the RLL. 
The initially present flow becomes zero after the balloon seal is achieved, flow returns when the 
catheter is withdrawn with subsequent loss of balloon seal, ruling out other potential causes of 
no flow. Panel B: Chartis measurement output of the RUL in the same patient, indicating absence 






Out of the 220 EBV cases, 36 patients (16%) had the right lower lobe as primary target 
for EBV. In 15 out of these 36 cases (42%) we performed a temporary right middle 
lobe occlusion with either a Watanabe spigot or balloon catheter in order to perform 
Chartis measurement of the right major fissure.
Therefore, 15 patients were included in the analysis (73% female, median FEV1 24% of 
predicted) (baseline characteristics are presented in table 1). Temporary right middle 
lobe occlusion was successful in all patients. The Watanabe spigot was used in 12 
cases. In 3 cases the balloon catheter was used because the use of the Watanabe 
spigot was not possible, because of a relatively large diameter entrance to the right 
middle lobe.
Table 1: Patient characteristics
Patient characteristics
Number of patients 15
Female/Male (%) 73/27
Age (years) 63 (47-73)
BMI (kg/m2) 22 (19-30)
Packyears (years) 43 (10-85)
FEV1 predicted(%) 24 (19-36)
RVpredicted (%) 229 (187-317)
RV/TLC (ratio) 0.65 (0.58-0.76)
6MWD (meter) 320 (15-484)
Data are presented as median (range) unless otherwise indicated. BMI: Body mass index; FEV1: 
forced expiratory volume in one second; RV: Residual volume; TLC: Total lung capacity; 6MWD: 
6-minute walking distance.
 
In all patients a reliable Chartis measurement could be performed after we placed 
the blocking device, and we did not observe a no flow phenomenon. In 13 out of 15 
patients (87%), the Chartis measurement in the right upper lobe indicated absence 
of collateral ventilation of the right major fissure. Six weeks after treatment, the 
median reduction in target lobe volume was 863ml and 9 out of 13 patients (69%) 
had achieved the minimal important difference for target lobe volume reduction 
of 563ml (11). See table 2 for Chartis measurement outcomes.
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Table 2: Chartis measurements
Chartis measurements
Total EBV cases (number)
Cases with RLL as primary EBV target (number)









Chartis measurement outcome right major fissure (CV negative/ CV positive) 13/2
Target Lobe Volume at baseline (ml) 1625 (1027-3001)
Target Lobe Volume Reduction at 6 weeks after treatment (ml) -863 (-3001-5)
Right major fissure integrity (%) 99 (95-100)
Right minor fissure integrity (%) 91 (58-98)
Data are presented as median (range) unless otherwise indicated. RML: Right middle lobe; EBV: 
Endobronchial valve. CV: collateral ventilation.
DISCUSSION
This case series provides insight in the use of two different approaches to temporary 
right middle lobe occlusion: Watanabe spigots and balloon catheters, to achieve 
reliable Chartis measurement outcomes. Using this technique, we were able to 
confirm the presence or absence of interlobar collateral ventilation of the right 
major fissure in all our patients, after initial measurement of the right lower lobe 
had failed. We considered both the insertion and removal of the Watanabe spigot 
and balloon catheter very feasible (see video in study supplement). While not 
structurally assessed in this case series, use of the blocking devices did not prolong 
Chartis measurement for more than several minutes. Although both blocking device 
approaches were feasible, in our practice, we generally reserve the use of a balloon 
catheter for patients with a relatively wide right middle lobe entrance, given its 
larger potential diameter (5-20mm) than the Watanabe spigot (5-7mm).
While temporary right middle lobe occlusion was already recommended by the 2017 
expert panel recommendations on EBV treatment, to the best of our knowledge no 
data was previously published on this technique (8).
Before the absence of flow during Chartis measurement is attributed to the no 
flow phenomenon, we recommend excluding other causes of absent flow: mucus 




and in addition correct catheter positioning should be verified. The catheter tip 
should not be in direct contact with the airway wall. While different terminology 
is used in the literature to describe the no flow phenomenon: for example “low 
flow” and “collapse phenomenon”, we suggest to describe this problem as the no 
flow phenomenon, as this description describes the clinical observation during 
measurement (5,7).
Previous studies have attributed the no flow phenomenon to dynamic expiratory 
airway collapse, in which airway collapse distal of the inflated Chartis balloon 
prevents expiratory airflow (5,7). While we consider this to be a valid explanation, the 
question remains why the lower lobes are more often affected by this phenomenon. 
A possible explanation may be the transpulmonary pressure gradient from the apical 
zones to the basal zones in combination with the emphysematous lung tissue. More 
research is required to confirm the exact physiological mechanism causing this 
phenomenon and its lower lobe predominance.
In conclusion, selective temporary occlusion of the right middle lobe using a 
blocking device, is helpful in obtaining a reliable Chartis outcome in case of the no 
flow phenomenon in the right lower lobe. The application of this simple technique 
may improve patient selection and outcomes for EBV treatment.
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Background: The St. George’s Respiratory Questionnaire (SGRQ) is a validated, 
commonly used questionnaire for measuring quality of life in patients with chronic 
obstructive pulmonary disease (COPD). The current established minimal important 
difference (MID) for SGRQ in an average COPD population is -4 units. However, for 
patients with severe COPD, the MID has not been thoroughly validated.
Objective: The objective of this study was to re-determine the MID for the SGRQ 
in patients with severe COPD.
Methods: We retrospectively included patients who participated in seven different 
bronchoscopic lung volume reduction clinical trials. Anchor- and distribution-based 
methods were used to define the MID for SGRQ. FEV1, 6-minute walk distance and 
residual volume were used as anchors.
Results: 115 severe COPD patients (mean ± SD, FEV1 26 ± 9% predicted, SGRQ 62 ± 
11 units), Combining both anchor- and distribution-based methods, we identified 
a SGRQ MID of -8.3 units at 1 month and -7.1 units at 6 months.
Conclusions: This study proposes an alternative SGRQ MID for patients with severe 
COPD of -8.3 units at 1 month and -7.1 units at 6 months follow-up after intervention. 
Our new MID estimates could be applied for both interpreting SGRQ outcomes as 
well as sample size determination in future clinical trials investigating interventions 
in severe COPD patients.
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INTRODUCTION
The St. George’s Respiratory Questionnaire (SGRQ) is a widely used, self-reported, 
quality of life assessment method to evaluate obstructive airways disease and 
especially Chronic Obstructive Pulmonary Disease (COPD) (1). When evaluating 
different treatment options for COPD it is relevant to investigate whether a 
statistically significant improvement is also clinically relevant. A method to describe 
this relationship is called the minimal important difference (MID) (2).
A decrease of 4 units, after a medical intervention, in the SGRQ score is generally 
accepted in the literature to be a valid threshold value of beneficial treatment (3). 
This threshold, or MID, is broadly applied in the evaluation of COPD-treatment for 
patients with a wide range of disease severity. However, patients with severe COPD 
have not been specifically included in previous MID calculations, knowing that 
their baseline SGRQ total scores are very high, making a 4-unit drop easy. In our 
own clinical experience, many patients with severe COPD improve more than 10 
units after bronchoscopic lung volume reduction treatment (4–6). Therefore, the 
established 4-unit MID for SGRQ might not be fully applicable to the severe COPD 
patient group. We hypothesised that the MID for SGRQ is higher in patients with 
severe COPD.




We performed a retrospective analysis on data from 7 completed bronchoscopic 
lung volume reduction (BLVR) clinical trials conducted in one hospital in the 
Netherlands (University Medical Center Groningen). Patients were treated with either 
airway bypass stents (www.clinicaltrials.gov identifier number: NCT00391612) (7)), 
coils (NCT01220908 (4) & NCT01328899 (8) & NCT01421082 (9)), valves (NCT01101958 
(6)) or foam-sealant (NCT01449292). Two trials (NCT00391612 (7) & NCT01101958(6)) 
included a control group and in total 19 control patients were included in our 
analyses. All trials had prior approval from the local medical ethical committee and 
all patients provided informed consent before participating. Patients were included 
in the analysis when 1 and/or 6 months post-treatment follow-up of the SGRQ 





Both the anchor-based as well as the distribution-based methods for determining the 
MID were used. For the anchor-based method, where the change in SGRQ outcome is 
compared to an established MID (2), the anchors chosen were: the forced expiratory 
volume in 1 second (FEV1)(MID 100ml (10)), 6-minute walk distance (6MWD)(MID 26 
meters (11)) and Residual Volume (RV) (MID 400ml (12)).
Distribution-based methods compare the change in outcome measure with 
some measure of variability (2). In this study, Cohen’s effect size was used, which 
is a frequently used distribution-based method in studies establishing MID’s 
in pulmonary medicine (11–13) and is one of the distribution-based methods 
recommended in the literature (2,14).
We calculated the final MID on basis of both the anchor- and distribution-based 
methods. The combined MID was calculated using the average of the 3 anchor-based 
and 1 distribution-based MID’s, each counting for 25% weight).
Measurements
The SGRQ consists of three subscales and a total score. Scores on SGRQ range 
from 0 to 100, with higher scores indicating worse quality of life. The total score 
summarizes the impact of the disease on overall health status (15). At baseline, 1 
month and 6 month follow-up the SGRQ was completed. Furthermore, spirometry 
and bodyplethysmography (Masterscreen™, Viasys, Germany) were performed 
according to the American Thoracic Society (ATS)/European Respiratory Society 
(ERS) guidelines (16,17) and a 6-minute walk test was performed according to the 
American Thoracic Society guidelines (18).
Data analysis
The absolute and relative change at 1 and 6 months follow-up compared to baseline 
were calculated. Pearson correlation coefficients (data were normally distributed) 
were calculated to test whether the univariate association between change in 
SGRQ score and change in anchor scores was sufficient to perform the anchor-
based method. A linear regression analysis was performed with change in SGRQ 
score as dependent variable and change in anchor score as independent variable. 
Afterwards, we entered the anchor-MID into the equation derived from the linear 
regression analysis. Subsequently, the MID could be calculated from the established 
equation. For the distribution-based method a moderate (0.5) Cohen’s effect size 
was calculated of the change score of SGRQ from baseline to 1 and 6 months follow-
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up. P-values <0.05 were considered significant. Statistical analyses were performed 
using IBM SPSS statistics version 22 (IBM, New York, USA).
RESULTS
115 patients had a baseline SGRQ measurement in combination with either a 1 or 
6 months follow-up SGRQ measurement and were included in the analyses. 110 
patients were included in the 1 month follow-up analysis and 86 patients were 
included in the 6 months follow-up analysis (see figure 1 for study flowchart).
 
Figure 1: Patient flowchart. SGRQ: St. George’s Respiratory Questionnaire.
 
Patient characteristics at baseline and change scores after 1 and 6 months follow-up 
are shown in table 1. At baseline, mean FEV1 was 26 ± 9% of predicted and the SGRQ 




Table 1: Patient characteristics at baseline and change at 1 and 6 months follow-up
Baseline 
(n=115)
% Predicted at 
Baseline ( n=115)
Δ1 month from 
baseline (n=110)
Δ6 months from 
baseline (n=86)
Females/Males 73/42 NA NA NA
Age (years) 60±8.8 NA NA NA
BMI (kg/m2) 24±3.6 NA 0.3±0.8 0.5±1.1
6MWD (meters) 311±95 NA 38.5±60.7 38.2±68.5
SGRQ Total score (units) 62±10.9 NA -9.8±13.8 -7.5±15.8
Packyears (years) 36±17 NA NA NA
RV (liter) 4.9±1.1 241±46.7 -0.5±0.6 -0.5±0.6
FEV1 (liter) 0.7±0.3 25.9±9.0 0.1±0.2 0.1±0.2
TLC (liter) 7.7±1.4 136±14.6 -0.2±0.4 -0.25±0.4
RV/TLC% 64.6±7.7 168±22.2 -4.0±5.7 -4.1±6.3
Data are presented as number or mean ± SD. Δ=change between baseline and follow-up. BMI: 
body mass index; FEV1: forced expiratory volume in 1 second; 6MWD: 6-minute walk distance; 
SGRQ: St George’s Respiratory Questionnaire; RV: residual volume; TLC: total lung capacity; NA: 
not applicable.
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Figure 2: Scatterplots of 6-minute walk distance (6MWD), RV (Residual Volume) and forced 
expiratory volume in 1 second (FEV1) versus St. George’s respiratory questionnaire (SGRQ) 
at 1 and 6 months follow-up. Panels A to C correspond to 1 month follow-up, panels D to F 
correspond to 6 months follow-up.
 
An association of r≥0.4 (P<0.05) was found between the change in SGRQ and change 




The outcomes of the calculations for the anchor-based, distribution-based and 
combined methods at 1 and 6 month follow-up are shown in table 2. At 1 month 
follow-up we calculated a MID for SGRQ of each anchor: RV -8.7 (relative -13.8%), 
FEV1 -9.2 (-13.0%) and 6MWD -8.5 (-15.3%). At 6 months follow-up we calculated 
a MID for RV of -6.4 (-10.2%), FEV1 -7.8 (-11.5%) and 6MWD -6.3 (-9.2%). With the 
distribution-based method, we calculated a MID for SGRQ at 1 month follow-up of 
-6.9 units (relative -11.3%) and at 6 months follow-up of -7.9 units (relative -13.3%). 
Our combined MID ( average of the 3 anchor-based and 1 distribution-based MID’s) 
proved -8.3 units (relative -13,4%) at 1 month and -7.1 units (relative -11.1%) at 6 
months.
Table 2: Minimal Important Differences for SGRQ
Absolute SGRQ 
MID 1 month 
(unit)
Relative SGRQ 
MID 1 month 
(%)
Absolute SGRQ 
MID 6 months 
(unit)
Relative SGRQ 


















Distribution-based: -6.9 -11.3% 7.9 -13.3%
Combined: -8.3 -13.4% -7.1 -11.1%
Data are presented as SGRQ units or percentage change compared to baseline. MID: Minimal 
Important Difference; SGRQ: St. George’s Respiratory Questionnaire; RV: residual volume; FEV1: 
Forced expiratory volume in 1 second; 6MWD: 6-minute walk distance.
DISCUSSION
To our knowledge, we established for the first time, a MID for SGRQ specifically for 
patients with severe COPD. Our findings differ substantially from the MID for SGRQ 
of -4 units that has been described more general in COPD (3). Our results showed 
that the MID for patients with severe COPD was -8.3 units at 1-month follow-up and 
-7.1 units at 6-months follow-up. The relative MID was -13.4% at 1-month follow-up 
and -11.1% at 6-months follow-up.
Our calculated MID for SGRQ for patients with severe COPD significantly differed 
compared to the earlier established MID (3). One explanation could be the chosen 
time points. In the article of Jones et al. it is not clear for which time point the MID for 
SGRQ was determined (3). Whilst inconclusive, most of their methods to establish the 
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MID are applied at the 12 month follow-up interval. In contrast, our MID estimations 
are established at the short term, after 1 and 6 months follow-up. At 6 months 
follow-up interval the established MID was lower compared to the 1 month follow-
up interval. It can be hypothesized that the diminished perceived effect of treatment 
results in lower decrease of SGRQ scores after 6 months follow-up. In the long-
term a MID could be further decreased due to the progressive nature of COPD. For 
example, although treatments may produce an initial improvement in SGRQ, scores 
may subsequently return to the baseline level or worse due to disease progression 
(19,20). More research is needed to investigate whether the MID in severe COPD 
patients at 12 months follow-up differ from our findings at 1 and 6 months follow-up.
Our study population consisted of patients who were treated with BLVR and the 
question rises whether our newly established MID is only applicable to this treatment 
or to other treatment modalities for patients with severe COPD as well. There is no 
consensus on whether a MID is applicable to a specific treatment or a broad range 
of treatment modalities. Jones states that MID’s were originally not developed in the 
context of specific treatments (21). He stated that the reference point (at least with 
anchor-based methods) is patient- or clinician-perceived benefit (21). Troosters et al. 
however question whether MID’s based on anchor techniques can be used across 
different interventions as several processes may underlie the observed effects of 
interventions. For example, the expectations of patients may be different, yielding 
different effect sizes with different interventions (22). Therefore, more research is 
needed regarding the specificity of MID’s for different treatments.
Several methods for estimating MID’s have been described in the literature, the 
most important being anchor-based and distribution-based methods (14). The 
combination of multiple methods is generally recommended to increase reliability 
of outcome (14). Therefore, we relied on both anchor-based and distribution-
based methods. The anchor-based method requires that a reasonably strong linear 
relationship exists between the anchor and the variable of interest (23). However, 
there is no consensus on how strong this relationship should be exactly. One review 
recommends statistically significant (p<0.05) correlation coefficients of ≥ 0.3 as 
appreciable (14) and two studies in COPD patients performed the analyses when 
correlation coefficients were 0.3 or 0.5 (11,24). In line with our previous study we 
chose a correlation coefficient threshold ≥ 0.4 (12). Distribution-based methods are 
commonly considered inferior to anchor-based methods because they rely solely 
on statistical criteria and depend heavily on the characteristics of a particular study 




should only be used to support estimates derived from anchor-based methods 
(2,14). Therefore, we have placed less weight on the distribution-based method in 
calculating our combined MID.
When performing an anchor-based analysis the quality of the anchors can influence 
the outcomes. A good anchor, in our opinion, is present if it is derived from several 
studies with comparable patient populations, in our case severe COPD patients. 
The anchor should be determined using several methods. Finally, there should be 
an appreciable association between the outcome variable and anchor (23). Here 
we will evaluate the strengths and weaknesses of the three anchors we used for 
our analysis. The 6MWD MID estimate was determined in a study investigating the 
effect of lung volume reduction surgery in severe COPD patients (11). Therefore, 
the patient population was quite comparable to ours but a different intervention 
was performed. Another study, which investigated the MID for 6MWD, found a 
similar outcome for treatment with pulmonary rehabilitation (24). This 6MWD 
anchor was moderately correlated with SGRQ scores in our study (r =0.5). The MID 
for RV was established in almost the same population as we used (93 patients 
overlap) and therefore is not the best anchor for establishing our MID (12). The 
MID was determined in one single study and to increase the reliability we feel it 
should be retested in more studies. The MID for RV was moderately associated with 
SGRQ (r =0.4). A positive feature of the MID for FEV1 is that it was determined in 
several studies comprising general COPD populations (10). A downside was that 
determining the MID of FEV1 was never the primary objective of these studies (10). 
In our study, FEV1 was moderately associated with SGRQ scores (r =0.4). In contrast 
to the anchor-based MID’s, the distribution-based MID’s were found to be higher 
at 6 months follow-up than at 1 month follow-up. This can be explained by the fact 
that, inherently to their methodology, distribution-based methods depend highly 
on variance in population. On 6 months follow-up the variance of measurements 
in the population is larger, leading to a higher distribution-based MID at 6 months, 
making it a more time-dependant method than the anchor-based method.
A limitation of our study is that most of our included studies were non-controlled. 
Another limitation of our study is that all our patients participated in trials 
investigating a BLVR treatment which is known to be a highly effective intervention 
resulting in a large decrease in SGRQ scores after treatment (25). This could affect 
the size of the MID estimates. Future studies, compromising multiple treatment-
modalities other than BLVR, are needed to confirm our findings.
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A strength of our study is that we were able to maintain a high level of standardization 
since all measurements were performed in one specialized research hospital in the 
Netherlands, applying the same settings/measurement sequence, using the same 
equipment. Furthermore, we had a, compared to most other MID determination 
studies, relatively large sample size (12,13,24).
In most studies determining a MID, results are solely expressed as absolute 
numbers. In our study we have also determined the relative MID’s. Relative MID’s 
are able to evaluate changes adjusted for baseline SGRQ-scores. We believe that 
when calculating a MID, besides the absolute MID also the relative MID should be 
estimated.
In conclusion, this study is the first to establish a MID SGRQ specifically for patients 
with severe COPD. Using a combination of anchor- and distribution-based methods 
we established a MID 1 month after treatment of -8.3 units and a MID of -7.1 after 6 
months. The relative MID 1 month after treatment was -13.4% and after 6 months 
-11.1%. Our new MID estimates could be applied for both interpreting SGRQ 
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Background: Target lobar volume reduction (TLVR) is an important efficacy outcome 
measure for bronchoscopic lung volume reduction (BLVR) treatment using one-
way endobronchial valves (EBV) in patients with severe emphysema. The commonly 
used cut-off value for TLVR that expresses a percievable clinical benefit is -350ml. 
However, a scientifically determined minimal important difference (MID) for TLVR 
never has been published.
Objective: The objective of this study was to determine the MID for TLVR on HRCT 
in patients who were treated with EBV.
Methods: A total of 318 severe emphysema patients from 2 BLVR trials were 
analysed. Anchor-based methods were used to define the TLVR MID at 6 months 
follow-up. Forced expiratory volume in 1 second (FEV1), residual volume (RV) and St. 
George’s Respiratory Questionnaire (SGRQ) were used as anchors.
Results: The calculated TLVR MID with each anchor was: FEV1 −587ml, RV −534ml and 
SGRQ -560ml. The combined MID (average of the 3 anchor-based MID’s) was −563ml.
Conclusions: Using the anchor-based method we established a TLVR MID of -563ml 
in patients with severe emphysema at 6 months follow-up after EBV treatment. This 
value can be useful for both interpreting the results from trials and clinical practice, 
as well as for designing future studies on lung volume reduction.
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INTRODUCTION
Patients with severe emphysema do not respond well to the current regular 
treatment options. Bronchoscopic lung volume reduction (BLVR) with endobronchial 
valves (EBV) is a valid treatment option for patients with severe emphysema and 
proven absence of collateral ventilation. BLVR treatment using EBV shows high 
efficacy and an acceptable safety profile (1–3). The purpose of EBV is to induce 
atelectasis in the most diseased lobe (“target lobe”) (figure 1). Like in surgical lung 
volume reduction, this approach reduces hyperinflation, resulting in improved 
function of the diaphragm and chest wall mechanics and consequent relief of 
dyspnea (4,5). The amount of target lobar volume reduction (TLVR) measured with 
high resolution computed tomography scans (HRCT) is one of the most important 
outcome measures of BLVR treatment using EBV since it has been shown to be an 
important predictor for clinically meaningful changes after this treatment (6).
The currently accepted, but solely expert opinion based, cut-off value for TLVR 
to reflect a meaningful clinical effect is a reduction of at least 350ml (7) using 
quantitative HRCT analysis, this was established on the basis that in the “VENT 
trial” the maximum TLVR in the control group receiving standard medical care 
rarely exceeded this level (8). To our knowledge, an objectively calculated minimal 
important difference (MID) for TLVR never has been published. In this respect the 
MID refers to the minimal TLVR that associates with significant improvements in 
clinically relevant outcomes of severe emphysema (9). We have seen many patients 
with severe emphysema improving far more than the 350ml cut-off value after 
BLVR treatment (1,7,10) and observed that the improvement might need to be 
more than the currently quoted 350ml to be appreciated by patients. Therefore, 
we hypothesized that the MID for TLVR is higher than the 350ml threshold in patients 
with severe emphysema.
The objective of this study was to determine the MID for TLVR in patients with severe 




Figure 1: Two images of a chest high resolution CT-scan pre (Panel A) and 6 months post (Panel 




We retrospectively analysed data from 2 large clinical trials investigating 
endobronchial valve treatment: The “STELVIO trial” (Netherlands Trial Register 
number NTR2876(1)) and the “VENT trial” (NCT00129584(8)). The STELVIO and VENT 
trial were approved by the ethics committees of all participating hospitals and all 
patients provided informed consent.
In total 68 patients participated in the STELVIO trial and 321 patients participated in 
the VENT trial. Patients were included in our analyses when they both had an HRCT 
at baseline and 6 months follow-up after EBV treatment.
Measurements
Patients in both trials underwent HRCT scans at baseline and 6 months after the 
treatment. TLVR was calculated using quantitative HRCT analysis.
In the “STELVIO trial” post-hoc computerized quantifications using Thirona Lung 
Quantification (version 15.01) (11) were performed on the data set to determine the 
amount of TLVR (figure 2). Spirometry and body plethysmography (MasterScreen™; 
VIASYS, Höchberg, Germany) at baseline and 6 months follow-up were performed 
according to the American Thoracic Society/European Respiratory Society guidelines 
(12).
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Figure 2: Three-dimensional reconstruction images of a chest high resolution CT-scan pre (plot 
A) and post (plot B) endobronchial valve treatment, showing a complete atelectasis of the left 
upper lobe which was associated with a TLVR of -1986ml, FEV1 increase of 260ml and RV decrease 
of 1.36L, 6 months after endobronchial valve treatment.
In the “VENT trial”, TLVR was measured by the study radiology core laboratory at 
the David Geffen School of Medicine (UCLA) through quantitative image analysis 
(MedQIA). Spirometry was performed based on the standardization of spirometry 
update by the American Thoracic Society (13) and body plethysmography was 
performed based on the American Association of Respiratory Care (AARC) clinical 
practice guideline (14) .
At baseline and at 6 months follow-up, patients in both trials were administered 
the full version of the St. George’s Respiratory Questionnaire, a quality of life 
questionnaire with scores ranging from 0 to 100, with higher scores indicating worse 
quality of life (15).
MID calculation
To determine the MID, an anchor-based approach was used. The anchor-based 
method uses external indicators whose clinical validity is established and with a 
demonstrated MID in the target population (16). For the anchor-based method, we 
considered forced expiratory volume in 1 second (FEV1) (MID 100ml (17)), residual 
volume (RV) (MID 430ml (18)), 6 minute walk distance (6MWD) (MID 26m (19)) and 
the St. George’s Respiratory Questionnaire (SGRQ) (MID 8 Units (20)) as anchors.





The absolute and relative changes from baseline to 6 months follow-up were 
calculated. For the anchor-based method, Pearson correlation coefficients were 
calculated. In line with our previous studies we considered a Pearson correlation 
coefficient of r≥0.4 to indicate a sufficiently strong association (18,20). Linear 
regression analyses were performed with change in TLVR as dependent variable and 
change in anchor score as independent variable. The MID’s of the anchors were then 
entered into the equations derived from the linear regression analyses. Afterwards, 
the MID could be calculated from the established equation. P<0.05 was considered 
statistically significant. All statistical analyses were performed using SPSS version 
22 (IBM, New York, NY, USA).
RESULTS
Seventeen patients in the “STELVIO trial”(1) and 54 patients in the “VENT trial” (8) did 
not perform an HRCT scan at 6 months follow-up and consequently 318 patients 
could be included in the analyses. Reasons for not completing the 6 months follow-
up were amongst others: ineligibility for treatment, patient decline for follow-up 
and EBV removal due to adverse events.
Patient characteristics at baseline and change in outcome parameters at 6 months 
follow-up are shown in table 1.
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Table 1: Patient characteristics at baseline and change scores between baseline and 6 months 
follow-up (Data are presented as mean ± standard deviation)






TLV (ml) 1807.3±514.2 -463.5±696.2
FEV1 (ml) 861.9±264.9 53.4±171.8
RV (liter) 4.70±1.14 -0.20±0.95
SGRQ Total score (units) 52.2±13.0 -4.3±13.9
Δ=change between baseline and follow-up. BMI: body mass index; TLV: Target Lobar Volume; 
FEV1: forced expiratory volume in 1 second; RV: residual volume; SGRQ: St. George’s Respiratory 
Questionnaire.
 
The Pearson correlation coefficient of TLVR with 6MWD was 0.32. This correlation 
coefficient did not meet the commonly accepted 0.40 correlation coefficient 
threshold and could therefore not be included as anchor in the MID calculation. The 
correlation coefficients and the MID calculations of the anchors are shown in table 2.
Scatterplots of correlations of TLVR versus FEV1, RV and SGRQ at 6 months follow-up 




Figure 3: Scatterplots and Pearson correlation coefficients of forced expiratory volume in 1 
second (FEV1), residual volume (RV) and St. George’s Respiratory Questionnaire (SGRQ) versus 
Target Lobar Volume Reduction (TLVR) at 6 months follow-up.
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We calculated a TLVR MID of each anchor at 6 months follow-up: FEV1 −587ml 
(relative MID −25.2%), RV −534ml (relative MID −21.3%) and SGRQ -560ml (relative 
MID -20.6%). Our combined MID (average of the 3 anchor-based MID’s) was −563ml 
(relative −22.4%) at 6 months follow-up.
Table 2: Minimal important differences for TLVR
Absolute TLVR MID at 6 months Relative TLVR MID at 6 months
Anchor:
FEV1 -587ml (r: 0.62)* -25.2% (r: 0.59)*
RV -534ml (r: 0.38)* -21.3% (r: 0.30)*
SGRQ -560ml (r: 0.40)* -20.6% (r: 0.26)*
Combined: -563ml -22.4%
TLVR: target lobar volume reduction; MID: minimal important difference; FEV1: forced expiratory 
volume in 1 second; RV: residual volume; SGRQ: St. George’s Respiratory Questionnaire; r: Pearson 
correlation coefficients. *) P<0.001
DISCUSSION
We have calculated for the first time a MID for TLVR in patients with severe 
emphysema. At 6 months follow-up after bronchoscopic lung volume reduction 
treatment using endobronchial valves the MID was –563ml and the relative MID 
was −22.4%. Our findings differ significantly from the currently accepted, expert 
opinion based, MID of 350ml.
The MID that we established was approximately 50% higher than the currently 
accepted cut-off value for TLVR of -350ml. Real data as basis for an MID for TLVR has 
never been published before and the cut-off value that is frequently used in the 
literature is based on expert opinion agreement. Based on our clinical experiences 
we hypothesized that the MID should be above the currently accepted 350ml 
threshold (7,10).
A possible contribution to this discrepancy is that the previous estimate of the MID 
was probably based on pulmonary function testing outcomes, underestimating the 
size of lung volume reduction due to the redistribution of lung volume from the 
target to the ipsilateral and contralateral lobes (21), leading to higher necessary HRCT 




All included patients underwent BLVR using EBV. The question rises whether MID’s 
based on anchor techniques can be used across different interventions as several 
processes may underlie the observed effects of interventions (22). Possibly, MID 
determination in patients who undergo lung volume reduction surgery or other 
bronchoscopic treatment modalities such as lung volume reduction coils, airway 
sealants or thermal vapor ablation could provide different MID results (23–26). 
Further research is required to assess the influence of different bronchoscopic 
treatment options on the TLVR MID calculation.
In this study we focused on the volume reduction of the target lobe and did not 
take into consideration for example the ipsi- or contralateral lobes. The ipsi- and 
contralateral lobes could expand after treatment. It is also possible that the character 
of the remaining lobe is of importance, for example emphysematous residual lung 
may offset the degree of lobar collapse. This might be investigated in future research.
There are different methods for the calculation of MID’s, for example anchor-based 
methods which are patient oriented and distribution-based methods which focus 
on distribution of outcomes. There is no consensus on the best methodology. One 
of the recommendations in the literature is that the MID should be based primarily 
on relevant patient-based and clinical anchors (16). Therefore, we used the anchor-
based method in this study. For the anchor-based method the choice of anchors can 
influence MID outcomes, therefore it is important to carefully select these anchors. 
One of the requirements for a good anchor is an high enough association between 
the anchor and the outcome variable (27). Despite the lower than 0.4 (0.38) Pearson 
correlation coefficient of the change in RV versus TLVR, the consistency of MID 
outcomes and our large sample size support the validity of our findings. Secondly, 
the anchor should be established in a comparable patient population. The anchors 
used in this study, with exception of the FEV1 anchor, were all established in patients 
who underwent BLVR to treat severe emphysema. Other studies determining MID’s 
included distribution-based methods as well (28,29). However a study by Turner et al. 
stated that the lack of consistency across distribution-based measures suggests that 
these approaches should act only as temporary substitutes, pending availability of 
empirically established anchor-based MID values (30). Terwee et al. even argue that 
distribution-based methods should not be used at all because they assess minimal 
detectable change, rather than minimal important change (31).
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A limitation of this study is that patients from 2 different BLVR trials were included. 
For example, the VENT trial (8) included patients with heterogeneous emphysema 
whereas the STELVIO trial (1) included patients with both heterogeneous and 
homogeneous emphysema and excluded patients with measured collateral 
ventilation. Furthermore, different lung function protocols were used in both 
spirometry as well as body plethysmography. However, patients underwent the 
same treatment and we were able to include a large number of patients compared 
to other studies determining MID’s. Furthermore, different volumetric quantification 
software analysis of the target lobes was performed in the 2 studies. Recent research 
suggests that the results from different software programs cannot always be 
considered interchangeable, however for longitudinal emphysema monitoring it 
was suggested that the scanning protocol and quantification software needs to 
be kept constant (32). In both studies used in our analysis, HRCT’s were performed 
following the same scanning protocol and with the same software programs at 
baseline and 6 months follow-up.
In conclusion, this study is the first to establish an MID for TLVR measured on 
HRCT scan in patients with severe emphysema. This value can be useful for both 
interpreting the results from trials and clinical practice, as well as for designing future 
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Bronchoscopic lung volume reduction (BLVR) is a treatment for patients with severe 
emphysema, aimed at reducing lung hyperinflation. It can be performed using 
different approaches, of which endobronchial valves and lung volume reduction 
coils are the most extensively investigated.
The goal of this thesis was to further advance the BLVR treatment by improving both 
the patient selection as well as the assessment of patient response after treatment. 
The results of the studies included in this thesis are summarized below.
Lung volume reduction coil treatment
In chapter 2 we reviewed the available evidence on the efficacy and safety of 
treatment with lung volume reduction coils in patients with severe emphysema, 
a treatment especially suitable for patients who are ineligible for endobronchial 
valve therapy (1). The three randomized controlled clinical trials investigating the 
treatment with lung volume reduction coils that were published so far, demonstrated 
significant improvement of pulmonary function outcomes and quality of life in 
patients with severe hyperinflation (2–4). This benefit comes with a price of coil 
treatment induced complications, which are mainly inflammatory in origin: COPD 
exacerbations, pneumonia and coil associated opacity (1).
Patient selection for bronchoscopic lung volume reduction
In chapter 3 we present the results of a large retrospective analysis of patients who 
were referred to our hospital to be evaluated for BLVR treatment. The aims of the 
study were twofold. Our first aim was to investigate which proportion of referred 
patients was actually selected for BLVR treatment, our secondary aim to identify 
differences in characteristics and survival between patients that were and were 
not selected for BLVR. In total, 1500 patients were included (mean age 62 years, 
50% female and forced expiratory volume in 1 second (FEV1) 33% of predicted). 
From this group only 19% was selected for BLVR treatment. Patients that were 
selected for BLVR lived significantly longer than the group of patients that was not 
selected for BLVR (median 3060 versus 2079 days, P<0.001). We found that only 
a small proportion of patients that is referred for BLVR treatment is eligible for a 
BLVR treatment, suggesting a large need for the development of new therapies for 
the group of patients that is currently not eligible for interventions. Furthermore, 
our data suggest that selection for BLVR treatment is associated with a significant 
survival benefit.
151
Summary, discussion and future perspectives
In chapter 4 we analysed differences in body plethysmography outcomes between 
patients referred for BLVR to our hospital and their referring hospitals. We observed 
a significantly lower (median 310ml difference) residual volume in our hospital, 
compared to the total of 62 referring hospitals (5). Overestimation of residual volume 
can lead to unnecessary referrals for BLVR and when ignored, potential treatment 
failures. To prevent the overestimation of residual volume, it is important that body 
plethysmography measurements are accurately performed, preferably using the 
unlinked method in patients with severe emphysema. During the unlinked method, 
the inspiratory capacity measurement is performed directly after the intrathoracic 
gas volume manoeuver and for the calculation of residual volume, the maximum 
vital capacity measured during spirometry is used.
Chapter 5 describes the validation of a new functional assessment tool, designed 
to improve target lobe selection for treatment with endobronchial valves (6). We 
demonstrated that the bronchoscopic measurement of lobar oxygen uptake is 
feasible to perform in patients with severe emphysema and that a lower oxygen 
uptake capacity was significantly associated with higher lobar emphysematous 
destruction and lower arterial and venous vascular volume of the target lobes. These 
findings suggest that this approach, allowing for the quantification of oxygen uptake 
capacity at a lobar level, can support the identification of a treatment target for lung 
volume reduction treatment with endobronchial valves. However, more research is 
required in order to further validate this approach.
In both chapter 6 and chapter 7, we investigated the effect of two different anesthesia 
techniques, procedural sedation and general anesthesia, on the bronchoscopic 
measurement of interlobar collateral ventilation (Chartis measurement). In 
chapter 6 we performed a retrospective analysis in which we analysed all Chartis 
measurements which were performed in our hospital between October 2010 and 
December 2017. We included 250 patients with emphysema (median FEV1 26% of 
predicted) and in total 746 Chartis readings were analysed. Performing Chartis 
measurement under general anesthesia was significantly faster and required less 
measurements when compared to procedural sedation, with no difference in target 
lobe volume reduction after treatment (7). In order to validate these findings, we 
performed a prospective trial comparing both anesthesia techniques. This study is 
presented in chapter 7, in which we prospectively compared Chartis measurement 
under procedural sedation versus general anesthesia. In this study, we confirmed 




general anesthesia is faster and more feasible to perform compared to procedural 
sedation, without affecting measurement outcomes (8).
In chapter 8, we discuss a technical solution for Chartis measurement of the 
right major fissure that is complicated by the no flow phenomenon. The no 
flow phenomenon, is a sudden cessation of flow is observed during Chartis 
measurement, caused by dynamic expiratory airway collapse and leads to an 
unreliable measurement (9). If this phenomenon occurs in the right lower lobe, 
when measuring collateral flow over the right major fissure, the entrance to the 
right middle lobe should be occluded and the Chartis balloon should be placed in 
the right upper lobe. In this study, we present a case series of 15 patients (median 
FEV1 24% of predicted) in which we demonstrated that temporary occlusion of the 
right middle lobe using a blocking device is feasible and that in this way a reliable 
Chartis measurement could be performed in all patients.
Assessment of response after treatment
In chapter 9, we established a new minimal important difference for the St. George’s 
Respiratory Questionnaire (SGRQ) in patients with severe chronic obstructive 
pulmonary disease (COPD) who were selected for BLVR (10). We used both anchor- 
and distribution-based methods to define the minimal important difference. We 
included 115 severe COPD patients (mean FEV1 26% of predicted, SGRQ score 62 
units) who participated in seven different BLVR clinical trials. We proposed a minimal 
important difference of -8.3 SGRQ units at 1 month and -7.1 units at 6 months after 
treatment (11). 
In chapter 10, we established a new minimal important difference for target lobe 
volume reduction after endobronchial valve treatment. We included 318 patients 
(mean FEV1 0.9l and target lobe volume 1807ml) from two BLVR clinical trials. Using 
an anchor-based approach, we established an MID of -563ml at 6 months after 
endobronchial valve treatment in patients with severe emphysema.
The minimal important differences established in chapter 9 and 10, can be useful 
for both interpreting the results from clinical trials and regular practice, as well as 
for designing future studies on bronchoscopic lung volume reduction.
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General discussion & future perspectives
Lung volume reduction coil treatment
The treatment with lung volume reduction coils can be considered in patients 
with emphysema, significant hyperinflation (RV >200% of predicted), who are not 
eligible for endobronchial valve treatment, but it remains under clinical investigation 
(12,13). A fourth, large prospective multicentre randomized controlled clinical trial 
comparing outcomes between lung volume reduction coils and a control group is 
underway to confirm the efficacy of this treatment (Clinicaltrials.gov: NCT03360396). 
In addition, a study investigating the effect of lung volume reduction on the lung 
microbiome is being performed (NCT03010566). Since only a small proportion 
of patients is eligible for endobronchial valve treatment, there is a clear need for 
alternative lung volume reduction techniques such as lung volume reduction coils. 
Future research should provide more insight in the exact mechanism of action, 
identify predictors of response, assess the durability of treatment benefit, investigate 
long term cost-effectiveness and potentially focus on new generation coil designs.
Patient selection
It is essential to carefully select patients for BLVR treatment, in order to achieve 
both safe and beneficial results. For example, interlobar collateral ventilation should 
be absent in order to achieve lobar atelectasis, and the treatment of patients with 
pleural adhesions increases the chance of pneumothorax after endobronchial 
valve treatment (14). Unfortunately, only a small proportion of patients that is 
referred for BLVR is considered eligible for these treatments. Therefore, new 
therapies should be developed for the population of patients with severe COPD 
that are currently considered ineligible for these interventions and who are 
unable to achieve satisfactory symptom control using regular medical therapy. 
In particular, for the treatment of patients with the severe chronic bronchitis 
phenotype of COPD, very limited treatment options are available. A new 
interventional therapy under development for chronic bronchitis is endobronchial 
treatment with liquid nitrogen cryospray, which is aimed at inducing an airway tissue 
healing effect by destroying hyperplastic goblet cells and excess submucous glands. 
However, until now, only the results from the first safety studies have been published 
and extensive research is required to investigate both the efficacy and safety profile of 
this treatment (15). Other novel experimental therapies include steam vapor ablation, 
which induces a reduction of lung volume by delivering water vapor, biological 
lung volume reduction, which uses a synthetic polymer in order to reduce lung 
volume and targeted lung denervation in which parasympathic pulmonary nerves 




Next to the development of new interventions, research is being performed 
aimed at increasing the proportion of patients eligible for currently available 
interventions. The ability to restore interlobar fissure integrity could potentially 
increase the number of patients eligible for endobronchial valve treatment. 
The “MIND THE GAP trial” (Dutch Trial Register: NTR5007) is designed to 
investigate the feasibility of injecting autologous blood or synthetic polymer 
into the interlobar collateral ventilation channels, to restore the integrity of the 
fissure. Another approach is proposed by Majid et al., who combined minimally 
invasive video assisted thoracic surgery (VATS), which allows for surgical stapling 
of the incomplete fissure, with the placement of endobronchial valves (19). 
In addition to the development of new therapies and efforts to increase the number 
of patients eligible for these treatments, the current first generation devices and 
delivery catheters of endobronchial valves and lung volume reduction coils could 
be evaluated and improved in new generations in order to provide easier handling, 
better biocompatibility, predictability of response, and potentially better functional 
outcomes.
Lung volume reduction surgery is still a valid treatment option in patients where 
a bronchoscopic approach is not an option, in patients with a predominantly 
paraseptal distribution of emphysema and in patients who have demonstrated 
significant initial effect after bronchoscopic treatment but where the effect was 
lost due to local complications or displacement of the valves (20). Between 2000 
and 2010, the number of lung volume reduction surgeries in the United States 
decreased significantly, a trend probably affected by the results of the NETT trial 
by Fishman et al., who found significant benefits of this treatment but at the cost 
of increased short term mortality and morbidity (21,22). However, between 2007 
and 2013 the number of lung volume reduction surgeries started to increase again, 
possibly because of improved surgical techniques and strict patient selection 
resulting in better outcomes (23,24). A randomized controlled study, comparing 
lung volume reduction surgery and endobronchial valve treatment (CELEB trial; 
International Standard Randomized Controlled Trial Number (ISRCTN:19684749)) 
is currently being performed in the United Kingdom. We expect that the further 
implementation of BLVR techniques and new insights in patient selection for these 
treatments, will further increase the number of lung volume reduction surgeries and 
that bronchoscopic and surgical lung volume reduction techniques can co-exist (20).
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Chartis measurement of interlobar collateral ventilation was originally validated 
under procedural sedation, in non-ventilated patients (25). Chartis measurement 
in patients who receive procedural sedation can be challenging for the physician 
performing this measurement because of issues with coughing, mucus and 
difficulties to maintain the right level of sedation (7). Arguments against Chartis 
measurement under general anesthesia could be the more extensive use of 
resources, the need for intubation and mechanical ventilation and the theoretical 
argument that ventilating patients using positive pressure might open collateral 
channels and consequently lead to false positive Chartis outcomes. However, no 
relevant difference in collateral ventilation outcome was observed in our prospective 
study between the two anesthesia techniques (8).
The 2019 expert recommendation guidelines for endobronchial valve treatment 
included the findings of our retrospective study and advised to perform Chartis 
measurement under general anesthesia (12). We confirmed the findings from our 
retrospective study in our prospective trial and we therefore advise to perform 
Chartis measurement under general anesthesia, preferably in the same session 
as the placement of the endobronchial valves (7,8). Performing both Chartis 
measurement and the placement of endobronchial valves in one procedure under 
general anesthesia is beneficial for the patient, as some hospitals perform separate 
procedures in which Chartis measurement is performed under procedural sedation, 
and these extra procedures can thus be avoided. There is no consensus yet in 
the literature on whether Chartis measurement can be replaced by quantitative 
CT analysis of fissure integrity in the future (26,27). Future research will have to 
clarify whether quantitative CT analysis is a strong enough independent predictor 
of collateral ventilation status or that bronchoscopic measurement remains 
indicated, perhaps in selected groups. In our opinion, Chartis measurement should 
be performed in every patient, as it is feasible to perform under general anesthesia 
and minimizes the chance of inappropriate endobronchial valve treatment in 
patients with positive interlobar collateral ventilation status, and subsequent patient 
disappointment.
While not the primary aim of the study, the results of our prospective study on 
the effect of anesthesia techniques on the feasibility and outcomes of Chartis 
measurement also provided insight in the occurrence of perioperative complications 
in patients with very severe emphysema (8). Based on this study and our clinical 
experience with our regular treatment program (BREATH-NL), we expect that the 




than is currently anticipated, provided that general anesthesia is administered 
under strictly controlled circumstances such as: the presence of an experienced 
anesthesiologist, patients with a stable disease state and adapted ventilator settings. 
We suggest to perform a study investigating this possibility, as the outcomes of 
such a study might affect a large population of patients with severe emphysema 
who are now considered ineligible for different surgical interventions under general 
anesthesia.
Selecting the most suitable target lobe for endobronchial valve treatment can 
sometimes be a challenging task. Target lobe selection is based on several 
characteristics: the degree of emphysema destruction, absence of collateral 
ventilation, lobar volume of the target lobe and ipsilateral lobe, heterogeneity 
between both lobes, low lobar perfusion assessed using perfusion scintigraphy and 
absence of pleural adhesions (28–30). Selection of the target lobe for endobronchial 
valve treatment is currently mainly based on indirect imaging techniques. Previous 
research by Freitag et al. demonstrated the use of bronchoscopic capnometry and 
oximetry curves, to aid in target lobe selection (31). We investigated a more direct 
approach to assess lobar function: assessment of lobar oxygen uptake capacity, 
which can provide insight in the functional capacity of individual lobes. The benefit 
of this measurement is that it provides real time information about lobar function 
during bronchoscopy and could even be integrated in the new generation of Chartis 
measurement systems (6). We recommend that in the future, integrated collateral 
ventilation and oxygen uptake capacity measurement of individual lobes will be 
used in the selection of potential target lobes for endobronchial valve treatment.
Assessment of response after treatment
The second aim of our thesis was to improve the assessment of response after BLVR 
treatment. We have established new minimal important differences for both the 
SGRQ and for target lobe volume reduction after endobronchial valve treatment 
(11,30).
Our newly established minimal important difference for target lobe volume 
reduction, could prove to be a valuable addition to the field, as target lobe 
volume reduction is one of the most frequently used outcome measures in studies 
investigating endobronchial valves. However, while the reduction in volume of the 
target lobe is essential to the treatment, it must be kept in mind that compensatory 
inflation of the ipsilateral lobe can occur.
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Therefore, the reduction in total lung volume might be more informative than 
solely the change in volume of the target lobe. In addition, in order to evaluate 
changes adjusted for high or low baseline scores, disease severity adjusted minimal 
important differences should be introduced (32). For example, while the minimal 
important difference for the SGRQ was established previously at -4 SGRQ units, our 
minimal important difference of -8.3 units at 1 month and -7.1 units at 6 months after 
treatment, might be more appropriate to use in patients with severe COPD (11,33). 
The concept of minimal important differences in general is still in development and 
some questions regarding the applicability and interpretation of minimal important 
differences remain unanswered. No consensus exists on whether minimal important 
differences should be assessed in a treatment- and disease severity-specific manner 
(34).
Most clinical trials investigating BLVR techniques already incorporated the proportion 
of patients achieving the minimal important differences after treatment: we encourage 
the inclusion of the proportion of patients achieving minimal important differences 
(responder rates) in future BLVR research and the respiratory field in general. 
The active engagement of patients when major health care decisions must be made 
is considered a cornerstone of patient centered care (35). A previous study found that 
the majority of patients with severe emphysema prefer a procedure comparable to 
endobronchial valve treatment over their current medical management (36). In our 
hospital, the balance between potential side effects and benefits is discussed with 
every potential candidate for BLVR treatment. Other examples of patient centered 
care might include the evaluation of patient reported goals, for example the ability 
to independently take a shower or take care of grandchildren, which might perhaps 
better reflect relevant improvement for the patient than the use of more traditional 
patient reported outcome measures (37).
Endobronchial valve treatment has been associated with prolonged survival, 
provided that successful lobar atelectasis is achieved (38–40). For lung volume 
reduction coil treatment, structural survival data is not yet available. Therefore, more 
research is needed to provide insight in long term survival after both endobronchial 





In conclusion, with the studies in this thesis, we have been able to obtain further 
insight in and contributed to the advancement of BLVR treatment in patients with 
severe emphysema. The studies described in this thesis may help the clinician in 
selecting the right patients for BLVR treatments and may provide more insight in the 
assessment and identification of patients with a meaningful clinical improvement 
of response after BLVR treatment.
The main results
I: Treatment with lung volume reduction coils as alternative for patients ineligible 
for endobronchial valves, results in significant improvement of pulmonary function 
outcomes and quality of life in patients with severe hyperinflation.
II: Only a small proportion of the patients referred for BLVR is eligible for treatment; 
when selected for treatment, significant survival benefit can be expected.
III: Measurement of lobar oxygen uptake can help to identify the least functional 
lobe and could be used as additional tool for endobronchial valve treatment target 
lobe selection.
IV: Chartis measurement is faster and more feasible to perform under general 
anesthesia compared to procedural sedation, without affecting measurement 
outcomes.
V: The minimal important differences for the St. George’s Respiratory Questionnaire 
and target lobe volume reduction are respectively -7.1 units and -563ml at 6 months 
after treatment.
The main future perspectives
Future research should be performed in order to:
I: Develop new therapies for the large population of patients with severe COPD that 
are currently considered ineligible for endobronchial interventions.
II: Increase the number of patients eligible for endobronchial valve treatment, for 
example by restoring interlobar fissure integrity.
III: Improve measurement of lobar function in order to guide target lobe selection 
for endobronchial valve treatment.
IV: Develop further insight in the applicability and interpretation of minimal 
important differences.
V: Provide insight in long term survival after bronchoscopic lung volume reduction
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Chronische obstructieve longziekte (COPD: “Chronic obstructive pulmonary disease”) 
is een chronische, progressieve longaandoening die wordt gekenmerkt door een 
vernauwing van de luchtwegen en verval van longblaasjes. Symptomen van COPD 
zijn onder andere kortademigheid, chronisch hoesten, toegenomen slijmproductie 
en een verhoogde vatbaarheid voor luchtweginfecties (1). Wereldwijd overleden 3 
miljoen mensen aan deze aandoening in 2016, daarmee is het de op twee na meest 
voorkomende doodsoorzaak (2). In Nederland hebben ongeveer 600,000 mensen 
COPD (3). De belangrijkste risicofactor voor het ontwikkelen van COPD is roken, maar 
ook beroepsmatige blootstelling aan stofdeeltjes, luchtvervuiling, blootstelling aan 
verbrandde biomassa en genetische aanleg kunnen bijdragen aan het ontstaan van 
deze aandoening. COPD kan worden onderverdeeld in verschillende fenotypen, 
waarvan luchtwegziekte (bronchitis) en destructie van de longblaasjes (emfyseem) 
de belangrijkste zijn (1).
Behandeling van COPD
COPD is een ongeneeslijke aandoening. De beschikbare behandelingen voor 
COPD zijn gericht op verlichting van symptomen en het vertragen van progressie. 
Voorbeelden van deze behandelingen zijn: stoppen met roken, luchtwegverwijdende 
en ontstekingsremmende medicatie, zuurstoftherapie, longrevalidatie, niet-
invasieve beademing en chirurgische interventies zoals longtransplantatie en 
longvolumereductie chirurgie.
Naast de bovengenoemde opties zijn bronchoscopische longvolumereductie 
behandelingen in opkomst. Deze behandelingen voor patiënten met het ernstig 
emfyseem fenotype van COPD, zijn gericht op het verminderen van “hyperinflatie” 
van de long. Hyperinflatie houdt in dat er, als gevolg van de COPD, een groter dan 
normale hoeveelheid lucht in de longen aanwezig is, die niet of niet snel genoeg 
kan worden uitgeademd. Deze hyperinflatie zorgt voor een toename van de 
kortademigheid en beperkt het inspanningsvermogen van de patiënt. Er bestaan 
verschillende vormen van bronchoscopische longvolumereductie, waarvan de 
behandelingen met éénrichtingsventielen en longvolumereductie coils het 
meest uitgebreid onderzocht zijn (4). Andere methoden van bronchoscopische 
longvolumereductie, zoals behandeling met stoom of synthetische polymeren zijn 




Bij de behandeling met éénrichtingsventielen wordt de ingang van een 
longkwab afgesloten met één of meerdere éénrichtingsventielen. Door deze 
éénrichtingsventielen kan er wel lucht uit deze longkwab stromen maar er niet 
meer terug in. Een longkwab waar geen lucht meer inkomt valt uiteindelijk samen, 
en dat is precies het doel van de behandeling met éénrichtingsventielen. Een 
voorwaarde voor effectief samenvallen is dat de scheiding (fissuur) tussen de 
behandelde en naastliggende longkwabben intact is en er dus geen luchtstroom 
(collaterale ventilatie) bestaat tussen deze longkwabben, waardoor de behandelde 
longkwab dus niet echt afgesloten is. Bij aanwezigheid van collaterale ventilatie zal 
de longkwab niet samenvallen na plaatsing van de éénrichtingsventielen en is de 
behandeling daarmee niet effectief (7).
Het is mogelijk om op basis van een CT-scan van de longen redelijk te voorspellen 
of er sprake is van collaterale ventilatie. Door middel van kwantitatieve CT analyse 
kan door software berekend worden of de fissuren tussen de 5 verschillende 
longkwabben intact zijn. Hoe intacter de fissuur is, hoe kleiner de kans op 
aanwezigheid van collaterale ventilatie (8).
Aanvullende informatie over collaterale ventilatie kan verkregen worden door 
middel van de “Chartis” meting. Tijdens de Chartis meting wordt de te behandelen 
longkwab afgesloten met een speciale ballonkatheter; hierna kan er gemeten 
worden hoeveel lucht er door de katheter uit de longkwab stroomt. Bij patiënten 
zonder collaterale ventilatie zal deze hoeveelheid lucht over de tijd geleidelijk 
afnemen omdat de longkwab leegloopt. Bij patiënten die wel collaterale ventilatie 
hebben zal deze hoeveelheid lucht constant blijven, er wordt dan immers nieuwe 
lucht aangevoerd vanuit de naastliggende longkwab naar de te meten longkwab (8).
Behandeling met longvolumereductie coils
Bij de behandeling met longvolumereductie coils worden speciale “coils” (spiralen), 
gemaakt van geheugenmetaal, met de bronchoscoop in de longen geplaatst. 
Deze coils krullen na plaatsing in de long op en zorgen voor het samentrekken 
van aangedaan longweefsel en daarmee de gewenste longvolumereductie. Deze 
behandeling kan ook worden uitgevoerd bij aanwezigheid van collaterale ventilatie 
tussen longkwabben en is dus een alternatief voor patiënten die niet in aanmerking 




Doel van het proefschrift
Het doel van dit proefschrift was tweeledig: ten eerste wilden we de selectie van 
patiënten voor bronchoscopische longvolumereductie verbeteren en daarnaast 
wilden we de uitkomsten na bronchoscopische longvolumereductie beter kunnen 
evalueren en interpreteren. De belangrijkste resultaten van de onderzoeken in dit 
proefschrift zijn hier samengevat.
Behandeling met longvolumereductie coils
In hoofdstuk 2 hebben we de beschikbare literatuur over effectiviteit en veiligheid 
van de behandeling met longvolumereductie coils voor patiënten met ernstig 
emfyseem onderzocht. Op dat moment waren er drie gerandomiseerde klinische 
studies gepubliceerd waarin deze behandeling werd onderzocht. Deze drie studies 
lieten allen significante verbeteringen zien in longfunctie en kwaliteit van leven 
(10–12). De complicaties die het vaakst werden gezien na deze behandeling waren 
COPD longaanvallen (exacerbaties), longontsteking en “coil associated opacity” (een 
lokale, niet infectieuze ontstekingsreactie rondom de coils) (9).
Patiënt selectie voor bronchoscopische longvolumereductie
In hoofdstuk 3 presenteren we de resultaten van een studie waarin we patiënten 
hebben onderzocht die werden verwezen naar ons ziekenhuis, om te beoordelen of 
ze in aanmerking kwamen voor een bronchoscopische interventie. Het hoofddoel 
van deze studie was om te onderzoeken hoeveel procent van de patiënten die 
werden verwezen naar ons ziekenhuis, ook daadwerkelijk in aanmerking kwamen 
voor een behandeling. Daarnaast hebben we onderzocht of er verschillen waren in 
patiëntkarakteristieken en overleving tussen patiënten die wél of niet geselecteerd 
werden voor een behandeling. In totaal includeerden we 1500 patiënten (gemiddeld 
62 jaar oud, 50% vrouw met een FEV1 van 33% van voorspeld). Van de totale groep 
verwezen patiënten werd slechts 19% geselecteerd voor bronchoscopische 
longvolumereductie behandeling. De belangrijkste redenen waarom patiënten niet 
geselecteerd werden voor behandeling waren: de afwezigheid van een geschikte 
behandelkwab, een ongeschikt COPD fenotype (bijvoorbeeld chronische bronchitis) 
en onvoldoende hyperinflatie. Patiënten die werden geselecteerd leefden significant 
langer dan de groep patiënten die niet werd geselecteerd voor de behandeling 
(mediane overleving na verwijzing 3060 dagen versus 2079 dagen).
Onze conclusie was dat slechts een klein deel van de patiënten die verwezen worden 
voor een bronchoscopische longvolumereductie behandeling hier daadwerkelijk 
voor in aanmerking komt. Dit geeft aan dat het erg belangrijk is om nieuwe 
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behandelingen te ontwikkelen voor de grote groep patiënten die op dit moment 
nog niet in aanmerking komt voor bronchoscopische interventies. Daarnaast 
suggereert onze data dat bronchoscopische longvolumereductie behandeling is 
geassocieerd met een significante overlevingswinst.
In hoofdstuk 4 hebben we verschillen in bodybox metingen vergeleken tussen 
ons ziekenhuis en de naar ons verwijzende ziekenhuizen, bij patiënten die waren 
verwezen voor een bronchoscopische behandeling. De bodybox meting is een 
methode om de totale inhoud van de longen en het residuaal volume te bepalen. 
Het residuaal volume is het volume lucht dat na een maximale uitademing in de 
longen achterblijft en is een maat voor de hoeveelheid hyperinflatie. In dit onderzoek 
constateerden we in ons ziekenhuis een significant lager residuaal volume dan in de 
verwijzende 62 ziekenhuizen (mediaan 310ml verschil). Aangezien alleen mensen 
met een hoog residuaal volume in aanmerking komen voor bronchoscopische 
longvolumereductie is dat een relevante bevinding: overschatting van het 
residuaal volume kan leiden tot onnodige verwijzingen en daarmee teleurstelling 
bij patiënten en onnodige zorgkosten. Om deze reden is het van belang dat de 
bodybox meting wordt uitgevoerd met specifieke aandacht voor de patiëntengroep 
met ernstig COPD. Een element hiervan is dat de longfunctie-analist die de meting 
uitvoert, ruim de tijd neemt om de patiënt volledig te laten uitademen tijdens de 
longfunctiemetingen: een uitdaging bij deze groep patiënten die problemen heeft 
met uitademen. Daarnaast heeft het de voorkeur dat de bodybox meting wordt 
uitgevoerd met de “unlinked” methode. Tijdens de unlinked methode wordt er voor 
het berekenen van de totale longcapaciteit, naast de gegevens van de bodybox 
meting, gebruik gemaakt van resultaten uit los uitgevoerd spirometrie onderzoek. 
Dit is in tegenstelling tot de “linked” methode waarin patiënten in de bodybox deze 
spirometrie metingen moeten uitvoeren. Deze “linked” combinatie van aansluitend 
een bodybox en spirometrie meting is uitdagend voor patiënten met ernstig COPD 
en zorgt daarmee voor een overschatting van het residuaal volume (13).
Hoofdstuk 5 beschrijft de validatie van een nieuwe meetmethode om de selectie 
van de behandelkwab voor éénrichtingsventielen te verbeteren. Tijdens deze 
meting wordt bepaald hoe goed een individuele longkwab zuurstof kan opnemen. 
De te meten longkwab wordt afgesloten middels een ballonkatheter, waarna wordt 
gemeten hoe snel de zuurstofconcentratie in de longkwab daalt. In deze studie 
laten we zien dat bronchoscopische meting van zuurstofopname-capaciteit van 
individuele longkwabben goed uitvoerbaar is. De belangrijkste bevinding van dit 




zowel een hogere mate van destructie van het longweefsel als met lagere arteriële 
en veneuze vaatvolumes van deze potentieel te behandelen longkwabben. Deze 
resultaten suggereren dat deze nieuwe selectieve bronchoscopische meting van 
zuurstofopname-capaciteit kan bijdragen aan het identificeren van de juiste te 
behandelen longkwab voor éénrichtingsventielen. Nader onderzoek is noodzakelijk 
om deze meting verder te valideren, maar we verwachten dat in de toekomst 
de selectie van te behandelen longkwabben voor éénrichtingsventielen vaker 
gebaseerd zal zijn op deze meting van functionele status, in aanvulling op de 
huidige beeldvormingstechnieken (14).
In hoofdstuk 6 en 7 hebben we het effect van twee typen anesthesie: sedatie 
(“roesje”) versus algehele narcose vergeleken op de bronchoscopische meting van 
collaterale ventilatie tussen longkwabben (de Chartis meting). Deze meting is van 
groot belang voor de behandeling met éénrichtingsventielen. Bij patiënten waarbij 
collaterale ventilatie (luchtstroom) tussen de verschillende longkwabben aanwezig 
is, zal deze behandeling namelijk niet tot het gewenste resultaat leiden. De Chartis 
meting is oorspronkelijk gevalideerd bij patiënten onder sedatie, die spontaan 
ademden (niet beademd werden) (15). In de praktijk bleek het echter lastig om deze 
meting onder sedatie uit te voeren: vaak traden er problemen op door hoesten van 
de patiënt, wat het op de juiste plaats houden van de katheter tijdens de meting 
lastig maakte, of waren er problemen met het stabiel houden van de sedatie (16). 
Deze problemen vormden de aanleiding om in hoofdstuk 6 en 7 uit te zoeken 
of er verschil was in Chartis uitkomsten tussen de meting onder sedatie of onder 
algehele narcose.
In hoofdstuk 6 hebben we een retrospectieve analyse uitgevoerd van alle 
Chartis metingen die in ons ziekenhuis werden uitgevoerd tussen Oktober 2010 
en December 2017. In deze studie includeerden we 250 patiënten met emfyseem 
en analyseerden we 746 Chartis metingen. Het uitvoeren van Chartis metingen 
onder algehele narcose ging sneller en er hoefden minder afzonderlijke metingen 
uitgevoerd te worden, vergeleken met het uitvoeren van de Chartis meting onder 
sedatie. Daarnaast vonden we geen verschil tussen de anesthesie technieken in de 
gewenste volume afname van de behandelde longkwabben (16). Om de resultaten 
uit hoofdstuk 6 te valideren hebben we een prospectieve studie opgezet om 
de anesthesie technieken te vergelijken. De resultaten van deze studie worden 
besproken in hoofdstuk 7. In deze studie werd de Chartis meting in elke patiënt 
uitgevoerd onder zowel sedatie als algehele narcose. Deze studie bevestigde de 
resultaten van onze retrospectieve studie: Chartis metingen onder algehele narcose 
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zijn sneller en makkelijker uit te voeren in vergelijking met Chartis meting onder 
sedatie, zonder dat dit negatieve invloed heeft op de uitkomsten van de meting (17).
In hoofdstuk 8 bespreken we een oplossing voor Chartis meting van de rechter 
fissura major (de scheiding tussen de onder- en bovenkant van de rechter long) 
die gecompliceerd wordt door een “no flow” fenomeen in de rechteronderkwab. 
Tijdens het “no flow” fenomeen, stopt de flow tijdens Chartis abrupt, wat leidt 
tot een onbetrouwbare meting (18). De theorie is dat dit wordt veroorzaakt door 
het samenvallen van de kleinere luchtwegen tijdens de meting (18). Wanneer 
dit fenomeen optreedt in de linkeronderkwab kan er worden uitgeweken naar 
de linkerbovenkwab om de linker fissura major door te meten. In de rechterlong 
zijn er echter drie longkwabben en twee fissuren, daarom kan er bij een “no flow” 
fenomeen in de rechteronderkwab niet zomaar in de rechterbovenkwab worden 
gemeten. De aanwezigheid van de rechtermiddenkwab kan bij die benadering 
leiden tot een fout-positieve uitkomst van de meting (de Chartis meting geeft aan 
dat er sprake is van collaterale ventilatie maar dit is niet daadwerkelijk het geval). Om 
alsnog een betrouwbare Chartis meting van de rechter fissura major te verkrijgen, 
dient de rechter middenkwab tijdelijk afgesloten te worden met een ‘blocking 
device’. Dit kan bijvoorbeeld met een “Watanabe spigot” of met een ballonkatheter. 
De Watanabe spigot is een siliconen plugje met een diameter van 7mm, die kan 
worden gebruikt om een luchtweg tijdelijk af te sluiten. Bij de ballon katheter kan 
een ballon, die zich aan het uiteinde van de katheter bevindt, worden opgeblazen 
tot een diameter tussen de 5 en 20mm. In deze studie presenteren we resultaten van 
15 longvolumereductie patiënten waarin we laten zien dat tijdelijke afsluiting van de 
rechtermiddenkwab met de Watanabe spigot of ballon katheter goed uitvoerbaar 
is en resulteerde in een betrouwbare Chartis meting in alle patiënten.
Beoordelen van het behandeleffect
Na een bronchoscopische longvolumereductie behandeling wordt er uitgebreid 
geëvalueerd in hoeverre er verbetering is in kwaliteit van leven en klinische 
uitkomsten voor de patiënt. In wetenschappelijk onderzoek wordt door middel van 
statistische testen getoetst of een verschil statistisch significant is (niet op toeval 
gebaseerd). Bij klinische studies met grote aantallen patiënten wordt regelmatig een 
klein maar statistisch significant verschil gevonden. Dit statistisch significant verschil 
is echter niet altijd ook een klinisch relevant verschil voor de patiënt. Daarom wordt 
ook wel het minimaal klinisch relevant verschil gebruikt. Dit is een afkapwaarde voor 




is: elk verschil dat groter is dan deze afkapwaarde wordt beschouwd als klinisch 
relevant.
In hoofdstuk 9, hebben we een nieuw minimaal klinisch relevant verschil (“minimal 
inportant difference (MID)”) berekend voor de kwaliteit van leven vragenlijst 
van het St. George ziekenhuis (SGRQ). De SGRQ vragenlijst wordt vaak gebruikt 
bij patiënten met COPD en meet de kwaliteit van leven van deze patiënten (19). 
Hoe hoger de score op deze vragenlijst, hoe slechter de kwaliteit van leven is. Er 
bestond al een MID voor de SGRQ, echter deze was niet gevalideerd voor patiënten 
met ernstig COPD (20). In onze studie hebben we 115 patiënten met ernstig COPD 
geïncludeerd (gemiddelde SGRQ score 62 punten) die deel hadden genomen aan 7 
verschillende studies naar bronchoscopische longvolumereductie. We hebben een 
MID vastgesteld van -8.3 SGRQ punten op 1 maand en -7.1 punten op 6 maanden 
na behandeling. Deze was wezenlijk hoger dan de oude MID voor de SGRQ van 
-4 punten. Deze nieuwe MID’s kunnen gebruikt worden voor de interpretatie van 
SGRQ uitkomsten in klinische studies en voor berekening van het minimum aantal 
patiënten dat nodig is om betrouwbare uitkomsten te verkrijgen in toekomstige 
studies naar interventies bij patiënten met ernstig COPD (21).
In hoofdstuk 10, hebben we de MID voor target lobe volume reduction (de 
gewenste afname van het volume van de behandelde longkwab) na behandeling 
met éénrichtingsventielen vastgesteld. Dit volume van longkwabben kan 
worden bepaald door middel van kwantitatieve CT analyse en is een belangrijke 
uitkomstmaat voor de behandeling met éénrichtingsventielen. Op het moment van 
uitvoeren van deze studie was er voor deze belangrijke uitkomst nog geen formele 
MID bepaald. We hebben 318 patiënten geïncludeerd (gemiddeld FEV1 0.9 liter en 
volume van de te behandelen longkwab 1807ml) uit 2 studies waarin patiënten 
werden behandeld met éénrichtingsventielen. We hebben een MID vastgesteld van 
-563ml op 6 maanden na behandeling met éénrichtingsventielen: het volume van 
de behandelde longkwab moet dus minimaal afnemen met 563ml om een klinisch 
relevant effect te bereiken. Deze MID kan zeer bruikbaar zijn in de klinische praktijk, 
bij de interpretatie van toekomstige wetenschappelijke onderzoeken en is daarnaast 





Met de studies beschreven in dit proefschrift hebben we nieuwe inzichten verkregen 
in en bijgedragen aan de ontwikkeling van bronchoscopische longvolumereductie 
behandelingen bij patiënten met ernstig emfyseem. Deze studies bieden de 
clinicus handvaten om de juiste patiënten te selecteren voor bronchoscopische 
longvolumereductie behandelingen en bieden nieuwe inzichten in de beoordeling 
en identificatie van patiënten met een klinisch relevante verbetering na de 
bronchoscopische longvolumereductie behandeling.
DE BELANGRIJKSTE BEVINDINGEN
I: Behandeling met longvolumereductie coils, als alternatief voor patiënten die geen 
kandidaat zijn voor éénrichtingsventielen, resulteert in significante verbetering van 
longfunctie en kwaliteit van leven bij patiënten met ernstige hyperinflatie.
II: Slechts een kleine selectie van de patiënten die worden verwezen voor 
bronchoscopische longvolumereductie komt in aanmerking voor behandeling; 
in het geval van selectie voor behandeling kan een significante overlevingswinst 
worden verwacht.
III: Meting van zuurstofopnamecapaciteit per longkwab kan bijdragen aan 
identificatie van de minst functionele longkwab en zo gebruikt worden bij het 
selecteren van een behandelkwab voor éénrichtingsventielen.
IV: Chartis metingen zijn sneller en makkelijker uit te voeren onder algehele narcose 
in vergelijking met sedatie, zonder dat dit de uitkomsten van de meting en de 
behandeling beïnvloedt.
V: Het minimaal klinisch relevant verschil voor de vragenlijst van het St. George 
ziekenhuis is -7.1 punten 6 maanden na bronchoscopische longvolumereductie.
VI: Het minimaal klinisch relevant verschil voor target lobe volume reductie is -563ml 
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